IDEXX Laboratories (IDXX) 10-Q 29 Oct 20 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2020	Oct. 26, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	000-19271
Entity Registrant Name	IDEXX LABORATORIES INC /DE
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	01-0393723
Entity Address, Address Line One	One IDEXX Drive
Entity Address, City or Town	Westbrook
Entity Address, State or Province	ME
Entity Address, Postal Zip Code	04092
City Area Code	207
Local Phone Number	556-0300
Title of 12(b) Security	Common Stock, $0.10 par value per share
Trading Symbol	IDXX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Outstanding (in shares)		85,299,893
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000874716
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 175,587	$ 90,326
Accounts receivable, net	337,593	269,312
Inventories	217,597	195,019
Other current assets	137,902	124,982
Total current assets	868,679	679,639
Long-Term Assets:
Property and equipment, net	547,624	533,845
Operating lease right-of-use assets	84,735	80,607
Goodwill	238,100	239,724
Intangible assets, net	53,467	58,468
Other long-term assets	254,802	240,192
Total long-term assets	1,178,728	1,152,836
TOTAL ASSETS	2,047,407	1,832,475
Current Liabilities:
Accounts payable	71,933	72,172
Accrued liabilities	362,326	322,938
Line of credit	0	288,765
Current portion of long-term debt	49,983	0
Current portion of deferred revenue	42,599	41,462
Total current liabilities	526,841	725,337
Long-Term Liabilities:
Deferred income tax liabilities	27,590	33,024
Long-term debt, net of current portion	853,316	698,910
Long-term deferred revenue, net of current portion	48,226	48,743
Long-term operating lease liabilities	70,655	67,472
Other long-term liabilities	79,664	81,164
Total long-term liabilities	1,079,451	929,313
Total liabilities	1,606,292	1,654,650
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued:106,282 shares in 2020 and 105,711 shares in 2019; Outstanding: 85,300 shares in 2020 and 85,471 shares in 2019	10,628	10,571
Additional paid-in capital	1,274,069	1,213,517
Deferred stock units: Outstanding: 147 units in 2020 and 143 units in 2019	5,411	4,462
Retained earnings	2,000,805	1,595,648
Accumulated other comprehensive loss	(61,925)	(46,182)
Treasury stock, at cost: 20,982 shares in 2020 and 20,240 shares in 2019	(2,788,412)	(2,600,543)
Total IDEXX Laboratories, Inc. stockholders’ equity	440,576	177,473
Noncontrolling interest	539	352
Total stockholders’ equity	441,115	177,825
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,047,407	$ 1,832,475

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (in USD per share)	$ 0.10	$ 0.10
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	106,282,000	105,711,000
Common stock, shares outstanding (in shares)	85,300,000	85,471,000
Deferred stock units, outstanding (in shares)	147,000	143,000
Treasury stock, shares (in shares)	20,982,000	20,240,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Total revenue	$ 721,789	$ 605,303	$ 1,985,717	$ 1,801,462
Cost of Revenue:
Total cost of revenue	299,183	260,353	824,179	767,062
Gross profit	422,606	344,950	1,161,538	1,034,400
Expenses:
Sales and marketing	108,202	104,551	318,526	312,499
General and administrative	105,031	66,337	231,111	186,653
Research and development	37,517	34,260	102,472	98,033
Income from operations	171,856	139,802	509,429	437,215
Interest expense	(8,110)	(7,090)	(25,297)	(23,662)
Interest income	208	86	417	159
Income before provision for income taxes	163,954	132,798	484,549	413,712
Provision for income taxes	17,633	23,960	77,376	76,464
Net income	146,321	108,838	407,173	337,248
Less: Net income attributable to noncontrolling interest	102	1	187	24
Net income attributable to IDEXX Laboratories, Inc. stockholders	$ 146,219	$ 108,837	$ 406,986	$ 337,224
Earnings per Share:
Basic (in dollars per share)	$ 1.71	$ 1.26	$ 4.77	$ 3.91
Diluted (in dollars per share)	$ 1.69	$ 1.24	$ 4.70	$ 3.85
Weighted Average Shares Outstanding:
Basic (in shares)	85,314	86,198	85,293	86,206
Diluted (in shares)	86,690	87,667	86,635	87,633
Product revenue
Revenue:
Total revenue	$ 422,283	$ 360,000	$ 1,153,114	$ 1,059,696
Cost of Revenue:
Total cost of revenue	146,804	125,112	396,282	370,388
Service revenue
Revenue:
Total revenue	299,506	245,303	832,603	741,766
Cost of Revenue:
Total cost of revenue	$ 152,379	$ 135,241	$ 427,897	$ 396,674

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 146,321	$ 108,838	$ 407,173	$ 337,248
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	7,329	(13,912)	(7,871)	(12,231)
Unrealized (loss) gain on Euro-denominated notes, net of tax (benefit) expense of $(890) and $(1,092) in 2020 and $947 and $1,105 in 2019	(2,824)	3,007	(3,466)	3,507
Unrealized (loss) gain on investments, net of tax (benefit) expense of $52 and $(129) in 2020 and $(21) and $93 in 2019	166	(67)	(408)	295
Unrealized gain (loss) on derivative instruments:
Unrealized gain (loss) on foreign currency exchange contracts, net of tax (benefit) expense of $(1,408) and $(161) in 2020 and $1,240 and $1,443 in 2019	(6,161)	5,348	(623)	6,458
Unrealized gain (loss) on cross currency swaps, net of tax (benefit) expense of $(933) and $(347) in 2020 and $733 and $892 in 2019	(3,941)	3,125	(1,339)	3,993
Reclassification adjustment for (gain) loss included in net income, net of tax (expense) benefit of $53 and $(526) in 2020 and $(688) and $(1,295) in 2019	538	(2,483)	(2,036)	(5,796)
Unrealized (loss) gain on derivative instruments	(9,564)	5,990	(3,998)	4,655
Other comprehensive (loss), net of tax	(4,893)	(4,982)	(15,743)	(3,774)
Comprehensive income	141,428	103,856	391,430	333,474
Less: Comprehensive income attributable to noncontrolling interest	102	1	187	24
Comprehensive income attributable to IDEXX Laboratories, Inc.	$ 141,326	$ 103,855	$ 391,243	$ 333,450

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Unrealized (loss) gain on Euro-denominated notes, tax (benefit) expense	$ (890)	$ 947	$ (1,092)	$ 1,105
Unrealized (loss) gain on investments, tax (benefit) expense	52	(21)	(129)	93
Unrealized gain (loss) on foreign currency exchange contracts, tax (benefit) expense	(1,408)	1,240	(161)	1,443
Unrealized gain (loss) on cross currency swaps, tax (benefit) expense	(933)	733	(347)	892
Reclassification adjustment for (gain) loss included in net income, tax expense	$ 53	$ (688)	$ (526)	$ (1,295)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative effect of accounting changes (Note 2)	Common Stock	Additional Paid-in Capital	Deferred Stock Units	Retained Earnings	Retained EarningsCumulative effect of accounting changes (Note 2)	Accumulated Other Comprehensive (Loss) Income	Treasury Stock	Noncontrolling Interest
Balance beginning of period (in shares) at Dec. 31, 2018			105,087
Balance beginning of period at Dec. 31, 2018	$ (9,233)		$ 10,509	$ 1,138,216	$ 4,524	$ 1,167,928		$ (41,791)	$ (2,288,899)	$ 280
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	102,709					102,681				28
Other comprehensive loss, net	1,776							1,776
Repurchases of common stock, net	(61,135)								(61,135)
Common stock issued under stock plans (in shares)			258
Common stock issued under stock plans	11,419		$ 26	11,393
Share-based compensation cost	6,334			6,266	68
Balance end of period (in shares) at Mar. 31, 2019			105,345
Balance end of period at Mar. 31, 2019	51,870		$ 10,535	1,155,875	4,592	1,270,609		(40,015)	(2,350,034)	308
Balance beginning of period (in shares) at Dec. 31, 2018			105,087
Balance beginning of period at Dec. 31, 2018	(9,233)		$ 10,509	1,138,216	4,524	1,167,928		(41,791)	(2,288,899)	280
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	337,248
Other comprehensive loss, net	(3,774)
Balance end of period (in shares) at Sep. 30, 2019			105,594
Balance end of period at Sep. 30, 2019	202,722		$ 10,559	1,189,554	4,416	1,505,152		(45,565)	(2,461,698)	304
Balance beginning of period (in shares) at Mar. 31, 2019			105,345
Balance beginning of period at Mar. 31, 2019	51,870		$ 10,535	1,155,875	4,592	1,270,609		(40,015)	(2,350,034)	308
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	125,701					125,706				(5)
Other comprehensive loss, net	(568)							(568)
Repurchases of common stock, net	(20,343)								(20,343)
Common stock issued under stock plans (in shares)			133
Common stock issued under stock plans	7,991		$ 13	8,556	(578)
Deferred stock units activity	0			(324)	324
Share-based compensation cost	6,898			6,855	43
Balance end of period (in shares) at Jun. 30, 2019			105,478
Balance end of period at Jun. 30, 2019	171,549		$ 10,548	1,170,962	4,381	1,396,315		(40,583)	(2,370,377)	303
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	108,838					108,837				1
Other comprehensive loss, net	(4,982)							(4,982)
Repurchases of common stock, net	(91,321)								(91,321)
Common stock issued under stock plans (in shares)			116
Common stock issued under stock plans	9,247		$ 11	9,247	(11)
Share-based compensation cost	9,391			9,345	46
Balance end of period (in shares) at Sep. 30, 2019			105,594
Balance end of period at Sep. 30, 2019	$ 202,722		$ 10,559	1,189,554	4,416	1,505,152		(45,565)	(2,461,698)	304
Balance beginning of period (in shares) at Dec. 31, 2019	105,711		105,711
Balance beginning of period at Dec. 31, 2019	$ 177,825	$ (1,829)	$ 10,571	1,213,517	4,462	1,595,648	$ (1,829)	(46,182)	(2,600,543)	352
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	111,856					111,827				29
Other comprehensive loss, net	(9,064)							(9,064)
Repurchases of common stock, net	(187,767)								(187,767)
Common stock issued under stock plans (in shares)			203
Common stock issued under stock plans	9,750		$ 20	9,730
Share-based compensation cost	7,284			7,238	46
Balance end of period (in shares) at Mar. 31, 2020			105,914
Balance end of period at Mar. 31, 2020	$ 108,055		$ 10,591	1,230,485	4,508	1,705,646		(55,246)	(2,788,310)	381
Balance beginning of period (in shares) at Dec. 31, 2019	105,711		105,711
Balance beginning of period at Dec. 31, 2019	$ 177,825	$ (1,829)	$ 10,571	1,213,517	4,462	1,595,648	$ (1,829)	(46,182)	(2,600,543)	352
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	407,173
Other comprehensive loss, net	$ (15,743)
Balance end of period (in shares) at Sep. 30, 2020	106,282		106,282
Balance end of period at Sep. 30, 2020	$ 441,115		$ 10,628	1,274,069	5,411	2,000,805		(61,925)	(2,788,412)	539
Balance beginning of period (in shares) at Mar. 31, 2020			105,914
Balance beginning of period at Mar. 31, 2020	108,055		$ 10,591	1,230,485	4,508	1,705,646		(55,246)	(2,788,310)	381
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	148,996					148,940				56
Other comprehensive loss, net	(1,786)							(1,786)
Issuances of common stock, net	258								258
Common stock issued under stock plans (in shares)			117
Common stock issued under stock plans	10,080		$ 12	10,068
Deferred stock units activity	0			(894)	894
Share-based compensation cost	7,797			7,797
Balance end of period (in shares) at Jun. 30, 2020			106,031
Balance end of period at Jun. 30, 2020	273,400		$ 10,603	1,247,456	5,402	1,854,586		(57,032)	(2,788,052)	437
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	146,321					146,219				102
Other comprehensive loss, net	(4,893)							(4,893)
Repurchases of common stock, net	(360)								(360)
Common stock issued under stock plans (in shares)			251
Common stock issued under stock plans	18,719		$ 25	18,706	(12)
Share-based compensation cost	$ 7,928			7,907	21
Balance end of period (in shares) at Sep. 30, 2020	106,282		106,282
Balance end of period at Sep. 30, 2020	$ 441,115		$ 10,628	$ 1,274,069	$ 5,411	$ 2,000,805		$ (61,925)	$ (2,788,412)	$ 539

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - $ / shares	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Statement of Stockholders' Equity [Abstract]
Common stock, par value (in USD per share)	$ 0.10	$ 0.10	$ 0.10	$ 0.10	$ 0.10	$ 0.10	$ 0.10	$ 0.10

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flows from Operating Activities:
Net income	$ 407,173	$ 337,248
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	71,437	65,422
Impairment charge	1,993	0
Provision for credit losses (Note 2 & Note 6)	5,235	618
Deferred income taxes	(3,363)	2,403
Share-based compensation expense	23,008	22,623
Other	488	879
Changes in assets and liabilities:
Accounts receivable	(72,409)	(24,451)
Inventories	(25,091)	(36,582)
Other assets and liabilities	30,579	(54,770)
Accounts payable	512	1,181
Deferred revenue	(10,433)	(10,826)
Net cash provided by operating activities	429,129	303,745
Cash Flows from Investing Activities:
Purchases of property and equipment	(92,768)	(109,058)
Acquisition of intangible assets	(668)	(255)
Acquisitions of a business and equity investment, net of cash acquired	(250)	(304)
Net cash used by investing activities	(93,686)	(109,617)
Cash Flows from Financing Activities:
Repayments on revolving credit facilities, net	(289,625)	(169,532)
Issuance of senior notes	200,000	100,000
Debt issuance costs	(4,995)	(154)
Payment of acquisition-related contingent consideration	(1,580)	(2,255)
Repurchases of common stock, net	(182,815)	(160,969)
Proceeds from exercises of stock options and employee stock purchase plans	39,230	28,739
Shares withheld for statutory tax withholding on restricted stock	(9,029)	(7,849)
Net cash used by financing activities	(248,814)	(212,020)
Net effect of changes in exchange rates on cash	(1,368)	(1,906)
Net increase (decrease) in cash and cash equivalents	85,261	(19,798)
Cash and cash equivalents at beginning of period	90,326	123,794
Cash and cash equivalents at end of period	175,587	103,996
Supplemental Cash Flow Information:
Cash paid for income taxes	79,909	80,036
Unpaid property and equipment, reflected in accounts payable and accrued liabilities	$ 7,708	$ 19,196

Basis of Presentation and Princ

Basis of Presentation and Principles of Consolidation	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION The accompanying unaudited condensed consolidated financial statements of IDEXX Laboratories, Inc. and its subsidiaries have been prepared in accordance with U.S. GAAP for interim financial information and with the requirements of Regulation S-X, Rule 10-01 for financial statements required to be filed as a part of this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “ IDEXX, ” the “ Company, ” “ we, ” “ our, ” or “ us ” refer to IDEXX Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements include the accounts of IDEXX Laboratories, Inc. and our wholly-owned and majority-owned subsidiaries. We do not have any variable interest entities for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements reflect, in the opinion of our management, all adjustments necessary for a fair statement of our financial position and results of operations. All such adjustments are of a recurring nature. The consolidated balance sheet data at December 31, 2019, was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and nine months ended September 30, 2020, are not necessarily indicative of the results to be expected for the full year or any future period, particularly in light of the COVID-19 pandemic and its effects on the domestic and global economies as described below. These unaudited condensed consolidated financial statements should be read in conjunction with this Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and our Annual Report on Form 10-K for the year ended December 31, 2019, (the “2019 Annual Report”) filed with the SEC. Beginning in the first quarter of 2020, to limit the spread of COVID-19, governments took various actions including the issuance of stay-at-home policies and social distancing procedures and guidelines, causing some businesses, including those that we serve, to adjust, reduce, or suspend business and operating activities. The primary impacts of the COVID-19 pandemic have been seen in our CAG and Water businesses. Veterinary care is widely recognized as an “essential” service for pet owners, and veterinarians continued to deliver essential medical care for sick and injured pets. The stay-at-home policies deployed early in 2020 to combat the spread of COVID-19 resulted in a decrease in companion animal clinical visits, including delay of elective procedures and wellness visits. Our reference laboratories and manufacturing facilities are operating and have been designated as essential businesses although disruptions or reductions to operations may occur as the impacts from the COVID-19 pandemic and related responses continue to develop. In order to maintain the quality of drinking and surface water, Water compliance testing is also recognized as an "essential" service; however, our business has been impacted due to lower non-compliance testing, as well as some disruption in compliance testing due to social distancing policies. During the second and third quarters of 2020, certain local, state, and federal governments began to ease the stay-at-home policies and allowed more businesses and facilities to re-open, leading to a recovery in companion animal clinical visits and associated demand for our diagnostic services. The extent to which the continuation, or a possible second-wave outbreak of COVID-19, or an outbreak of other health epidemics could impact our business, results of operations and financial condition, including the potential for write-offs or impairments of assets and suspension of capital investments, will depend on future developments. We are unable to predict with certainty the effects of the COVID-19 pandemic on our customers, suppliers, and vendors, as well as the actions of governments, and when and to what extent normal economic and operating conditions can resume; these effects may differ from those assumed in our projected estimates. Even after the COVID-19 pandemic has subsided, we may continue to experience adverse impacts to our business as a result of any economic impact that has occurred or may occur in the future. The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues, and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments, and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity, and the amount of revenues and expenses. We have made estimates of the impact of the COVID-19 pandemic within our financial statements, and our actual results may differ from these estimates and there may be changes to those estimates in future periods. We have included certain terms and abbreviations used throughout this Quarterly Report on Form 10-Q in the “Glossary of Terms and Selected Abbreviations.”

Accounting Policies

Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Accounting Policies	ACCOUNTING POLICIES Significant Accounting Policies The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements as of and for the three and nine months ended September 30, 2020, are consistent with those discussed in Note 2. Summary of Significant Accounting Policies to the consolidated financial statements in our 2019 Annual Report, except as noted below. New Accounting Pronouncements Adopted Effective January 1, 2020, we adopted ASU 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosure requirements on fair value measurements under ASC Topic No. 820, Fair Value Measurement, as amended (“ASC 820”). ASU 2018-13 removes (a) the prior requirement to disclose the amount and reason for transfers between Level 1 and Level 2 of the fair value hierarchy contained in ASC 820, (b) the policy for timing of transfers between levels, and (c) the valuation processes used for Level 3 fair value measurements. ASU 2018-13 also adds, among other things, a requirement to disclose the range and weighted average of significant unobservable inputs used in Level 3 fair value measurements. The adoption did not have a material impact on our consolidated financial statements. Effective January 1, 2020, we adopted ASU 2016-13 New Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” The new guidance is intended to simplify the accounting for income taxes by removing certain exceptions and by updating accounting requirements around goodwill recognized for tax purposes and the allocation of current and deferred tax expense among legal entities, among other minor changes. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. We do not expect the adoption of ASU 2019-12 to have a material impact on our consolidated financial statements. In March 2020, the FASB issued ASU 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” ASU 2020-04 is intended to provide optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the discontinuation of the London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued. The relief offered by this guidance, if adopted, is availa ble to companies for the period March 12, 2020 through December 31, 2022. We do not expect the discontinuation of LIBOR to h ave a material impact on our consolidated financial statements.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition	REVENUE RECOGNITION Our revenue is recognized when, or as, performance obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to a customer. We exclude sales, use, value-added, and other taxes we collect on behalf of third parties from revenue. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer. To accurately present the consideration received in exchange for promised products or services, we apply the five-step model outlined below: 1. Identification of a contract or agreement with a customer 2. Identification of our performance obligations in the contract or agreement 3. Determination of the transaction price 4. Allocation of the transaction price to the performance obligations 5. Recognition of revenue when, or as, we satisfy a performance obligation We enter into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The timing of revenue recognition, billings, and cash collections results in accounts receivable, contract assets and lease receivables as a result of revenue recognized in advance of billings (included within other assets), and contract liabilities or deferred revenue as a result of receiving consideration in advance of revenue recognition within our unaudited condensed consolidated balance sheet. Our general payment terms range from 30 to 60 days, with exceptions in certain geographies. Below is a listing of our major categories of revenue for our products and services: Diagnostic Products and Accessories . Diagnostic products and accessories revenues, including IDEXX VetLab ® consumables and accessories, rapid assay, LPD, Water, and OPTI testing products, are predominantly recognized and invoiced at the time of shipment, which is when the customer obtains control of the product based on legal title transfer and we have the right to payment. Shipping costs reimbursed by the customer are included in revenue and cost of sales. As a practical expedient, we do not account for shipping activities as a separate performance obligation. Reference Laboratory Diagnostic and Consulting Services . Reference laboratory revenues are recognized and invoiced when the laboratory diagnostic service is performed. Instruments, Software and Systems . CAG Diagnostics capital instruments, veterinary software and diagnostic imaging systems revenues are recognized and invoiced when the customer obtains control of the products based on legal title transfer and we have the right to payment, which generally occurs at the time of installation and customer acceptance. Our instruments, software, and systems are often included in one of our significant customer programs, as further described below. For veterinary software systems that include multiple performance obligations, such as perpetual software licenses and computer hardware, we allocate revenue to each performance obligation based on estimates of the price that we would charge the customer for each promised product or service if it were sold on a standalone basis. Lease Revenue . Revenues from instrument rental agreements and reagent rental programs are recognized either as operating leases on a ratable basis over the term of the agreement or as sales-type leases at the time of installation and customer acceptance. Customers typically pay for the right to use instruments under rental agreements in equal monthly amounts over the term of the rental agreement. Our reagent rental programs provide our customers the right to use our instruments upon entering into agreements to purchase specified amounts of consumables, which are considered embedded leases. For some agreements, the customers are provided with the right to purchase the instrument at the end of the lease term. Lease revenues from these agreements are presented in product revenue on our unaudited condensed consolidated income statement. Lease revenue was approxima tely $4.5 million and $12.2 million for t he three and nine months ended September 30, 2020, respectively, as compared to $5.3 million and $14.5 million for the three and nine months ended September 30, 2019, respectively, including both operating leases and sales-type leases under ASC 842, Leases, for leases entered into after January 1, 2019, and ASC 840, Leases, for leases entered into prior to 2019. See below for revenue recognition under our reagent rental programs. Extended Warranties and Post-Contract Support . CAG Diagnostics capital instruments and diagnostic imaging systems extended warranties typically provide customers with continued coverage for a period of one Veterinary software post-contract support provides customers with access to technical support when and as needed through access to call centers and online customer assistance. Post-contract support contracts typically have a term of 12 months and customers are billed for post-contract support in equal quarterly amounts over the term. We recognize revenue for post-contract support services over time on a ratable basis using a time elapsed measure of performance over the contract term, which approximates the expected timing in which applicable services are performed. On December 31, 2019, our deferred revenue related to extended warranties and post-contract support was $38.0 million, of which approximately $2.8 million and $19.5 million were recognized during the three and nine months ended September 30, 2020. Furthermore, as a result of new agreements, our deferred revenue related to extended warranties and post-contract support w as $35.2 million at September 30, 2020. We do not disclose information about remaining performance obligations that are part of contracts with an original expected duration of one year or less and do not adjust for the effect of the financing components when the period between customer payment and revenue recognition is one year or less. Deferred revenue related to extended warranties and post-contract support with an original duration of more than one year was $21.2 million at September 30, 2020, of which approximately 11%, 40%, 28%, 14%, and 7% are expected to be recognized during the remainder of 2020, the full years 2021, 2022, 2023, and thereafter, respectively. Additio nally, we have determined these agreements do not include a significant financing component. SaaS Subscriptions . We offer a variety of veterinary software and diagnostic imaging SaaS subscriptions including IDEXX Neo ® , Animana ® , Pet Health Network ® Pro, Petly ® Plans, Web PACS, rVetLink ® , and Smart Flow ™ . We recognize revenue for our SaaS subscriptions over time on a ratable basis over the contract term, beginning on the date our service is made available to the customer. Our subscription contracts vary in term from monthly to two years. Customers typically pay for our subscription contracts in equal monthly amounts over the term of the agreement. Deferred revenue related to our SaaS subscriptions is not material. Contracts with Multiple Performance Obligations . We enter into contracts where customers purchase a combination of IDEXX products and services. Determining whether products and services are considered distinct performance obligations that should be accounted for separately requires significant judgment. We determine the transaction price for a contract based on the consideration we expect to receive in exchange for the transferred goods or services. To the extent the transaction price includes variable consideration, such as volume rebates or expected price adjustments, we apply judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. We evaluate constraints based on our historical and projected experience with similar customer contracts. We allocate revenue to each performance obligation in proportion to the relative standalone selling prices and recognize revenue when transfer of the related goods or services has occurred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. When standalone selling prices for our products or services are not directly observable, we determine the standalone selling prices using relevant information available and apply suitable estimation methods including, but not limited to, the cost plus a margin approach. We recognize revenue as each performance obligation is satisfied, either at a point in time or over time, as described in the revenue categories above. We do not disclose information about remaining performance obligations that are part of contracts with an original expected duration of one year or less. The following customer programs represent our most significant customer contracts which contain multiple performance obligations: Customer Commitment Programs . We offer customer incentives upon entering into multi-year agreements to purchase annual minimum amounts of products and services. Up-Front Customer Loyalty Programs . Our up-front loyalty programs provide customers with incentives in the form of cash payments or IDEXX Points upon entering into multi-year agreements to purchase annual minimum amounts of future products or services. If a customer breaches its agreement, they are required to refund all or a portion of the up-front cash or IDEXX Points, or make other repayments, remedial actions, or both. Up-front incentives to customers in the form of cash or IDEXX Points are not made in exchange for distinct goods or services and are capitalized as customer acquisition costs within other current and long-term assets, which are subsequently recognized as a reduction to revenue over the term of the customer agreement. If these up-front incentives are subsequently utilized to purchase instruments, we allocate total consideration, including future committed purchases less up-front incentives and estimates of expected price adjustments, based on relative standalone selling prices to identified performance obligations and recognize instrument revenue and cost at the time of installation and customer acceptance. To the extent invoiced instrument revenue exceeds recognized instrument revenue, we record deferred revenue as a contract liability, which is subsequently recognized upon the purchase of future products and services. We have determined these agreements do not include a significant financing component. Differences between estimated and actual customer purchases may impact the amount and timing of revenue recognition. On December 31, 2019, our capitalized customer acquisition costs were $137.4 million, of which approximately $9.7 million and $29.9 million were recognized as a reduction of revenue during the three and nine months ended September 30, 2020. Furthermore, as a result of new up-front customer loyalty payments, net of subsequent recognition, our capitalized customer acquisition costs w ere $146.0 million at September 30, 2020 . We monitor customer purchases over the term of their agreement to assess the realizability of our capitalized customer acquisition costs and review estimates of variable consideration. Impairments, revenue adjustments that relate to performance obligations satisfied in prior periods, and contract modifications during the three and nine months ended September 30, 2020, were not material. Volume Commitment Programs . Our volume commitment programs, such as our IDEXX 360 program, provide customers with a free or discounted instrument or system upon entering into multi-year agreements to purchase annual minimum amounts of products and services. We allocate total consideration, including future committed purchases and expected price adjustments, based on relative standalone selling prices to identified performance obligations and recognize instrument revenue and cost at the time of installation and customer acceptance in advance of billing the customer, which is also when the customer obtains control of the instrument based on legal title transfer. Our right to future consideration related to instrument revenue is recorded as a contract asset within other current and long-term assets. The contract asset is transferred to accounts receivable when customers are billed for future products and services over the term of the contract. We have determined these agreements do not include a significant financing component. Differences between estimated and actual customer purchases may impact the amount and timing of revenue recognition. On December 31, 2019, our volume commitment contract assets were $83.9 million, of which approximately $4.5 million and $14.0 million were reclassified to accounts receivable when customers were billed for related products and services during the three and nine months ended September 30, 2020. Furthermore, as a result of new placements under volume commitment programs, net of subsequent amounts reclassified to accounts receivable, and allowances established for credit losses upon adoption of ASU 2016-13, our contract assets we re $101.3 million at September 30, 2020. We monitor customer purchases over the term of their agreement to assess the realizability of our contract assets and review estimates of variable consideration. Impairments, revenue adjustments that relate to performance obligations satisfied in prior periods, and contract modifications during the three and nine months ended September 30, 2020, were not material. For our up-front customer loyalty and volume commitment programs, we estimate future revenues related to multi-year agreements to be approxima tely $2.0 billion, of which approximately 7%, 25%, 23%, 20%, and 25% ar e expected to be recognized during the remainder of 2020, the full years 2021, 2022, 2023, and thereafter, respectively. These future revenues relate to performance obligations not yet satisfied, for which customers have committed to purchase goods and services, net of the expected revenue reductions from customer acquisition costs and expected price adjustments, and as a result, are lower than stated contractual commitments by our customers. Instrument Rebate Programs . Our instrument rebate programs, previously referred to as IDEXX Instrument Marketing Programs, require an instrument purchase and provide customers the opportunity to earn future rebates based on the volume of products and services they purchase over the term of the program. We account for the customer’s right to earn rebates on future purchases as a separate performance obligation and determine the standalone selling price based on an estimate of rebates the customer will earn over the term of the program. Total consideration allocated to identified performance obligations is limited to goods and services that the customer is presently obligated to purchase and does not include estimates of future purchases that are optional. We allocate total consideration to identified performance obligations, including the customer’s right to earn rebates on future purchases, which is deferred and recognized upon the purchase of future products and services, offsetting future rebates as they are earned. On December 31, 2019, our deferred revenue related to instrument rebate programs was $49.1 million, of which approximately $4.0 million and $12.5 million were recognized when customers purchased eligible products and services and earned rebates during the three and nine months ended September 30, 2020, respectively. Furthermore, as a result of new instrument purchases under rebate programs, net of subsequent recognition, our deferred revenu e was $41.0 million at September 30, 2020, of which approximately 10%, 34%, 25%, 16%, and 15% are expected to be recognized during the remainder of 2020, the full years 2021, 2022, 2023, and thereafter, respectively. Reagent Rental Programs . Our reagent rental programs provide our customers the right to use our instruments upon entering into multi-year agreements to purchase annual minimum amounts of consumables. These types of agreements include an embedded lease for the right to use our instrument, and we determine the amount of lease revenue allocated to the instrument based on relative standalone selling prices. We evaluate the terms of these embedded leases to determine classification as either a sales-type lease or an operating lease. Sales-type Reagent Rental Programs . Our reagent rental programs that effectively transfer control of instruments to our customers are classified as sales-type leases, and we recognize instrument revenue and cost in advance of billing the customer, at the time of installation and customer acceptance. Our right to future consideration related to instrument revenue is recorded as a lease receivable within other current and long-term assets, and is transferred to accounts receivable when customers are billed for future products and services over the term of the contract. On December 31, 2019, our lease receivable assets were $7.2 million, of which approxim ately $0.3 million and $1.0 million were reclassified to accounts receivable when customers were billed for related products and services during the three and nine months ended September 30, 2020, respectively. Furthermore, as a result of new placements under sales-type reagent rental programs, net of subsequent amounts reclassified to accounts receivable, and allowances established for credit losses upon adoption of ASU 2016-13, our lease receivable ass ets were $9.2 million at September 30, 2020. The impacts of discounting and unearned income at September 30, 2020, were not material. Profit and loss recognized at the commencement date and interest income during the three and nine months ended September 30, 2020, were not material. We monitor customer purchases over the term of their agreement to assess the realizability of our lease receivable assets. Impairments during the three and nine months ended September 30, 2020, were not material. Operating-type Reagent Rental Programs . Our reagent rental programs that do not effectively transfer control of instruments to our customers are classified as operating leases, and we recognize instrument revenue and costs ratably over the term of the agreement. The cost of the instrument is capitalized within property and equipment. During the three and nine months ended September 30, 2020, we transferred instrume nts of $2.6 million and $6.6 million, respecti vely, as compared to $5.5 million and $10.5 million for the three and nine months ended September 30, 2019, respectively, from inventory to property and equipment. We estimate future revenue to be recognized related to our reagent rental program s of approximately $25.9 million, of which approximately 11%, 37%, 24%, 13%, and 15% are expected to be recognized during the remainder of 2020, the full years 2021, 2022, 2023, and thereafter, respectively. These future revenues relate to performance obligations not yet satisfied for which customers have committed to future purchases, net of any expected price adjustments, and as a result, may be lower than stated contractual commitments by our customers. Other Customer Incentive Programs . Certain agreements with customers include discounts or rebates on the sale of products and services applied retrospectively, such as volume rebates achieved by purchasing a specified purchase threshold of goods and services. We account for these discounts as variable consideration and estimate the likelihood of a customer meeting the threshold in order to determine the transaction price using the most predictive approach. We typically use the most-likely-amount method for incentives that are offered to individual customers and the expected-value method for programs that are offered to a broad group of customers. Revenue adjustments that relate to performance obligations satisfied in prior periods during the three and nine months ended September 30, 2020, were not material. Refund obligations related to customer incentive programs are recorded in accrued liabilities for the actual issuance of incentives, incentives earned but not yet issued and estimates of incentives to be earned in the future. Program Combinations . At times, we combine elements of our significant customer programs within a single customer contract. We separate each significant program element and include the contract assets, customer acquisition costs, deferred revenues and estimated future revenues within the most relevant program disclosures above. Each customer contract is presented as a net contract asset or net contract liability on our unaudited condensed consolidated balance sheet. IDEXX Points . IDEXX Points may be applied to trade receivables due to us, converted to cash, or applied against the purchase price of IDEXX products and services. We consider IDEXX Points equivalent to cash. IDEXX Points that have not yet been used by customers are included in accrued liabilities until utilized or expired. Breakage is not material because customers can apply IDEXX Points to trade receivables at any time. Accounts Receivable . We recognize revenue when it is probable that we will collect substantially all of the consideration to which we will be entitled, based on the customer’s intent and ability to pay the promised consideration. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s historical payment experience or, in the case of a new customer, published credit and financial information pertaining to the customer. We have no significant customers that accounted for greater than 10% of our consolidated revenues, and we have no concentration of credit risk as of September 30, 2020. Disaggregated Revenues . We present disaggregated revenue for our CAG segment based on major product and service categories. Our Water segment is comprised of a single major product category. Although our LPD segment does not meet the quantitative thresholds to be reported as a separate segment, we believe it is important to disaggregate these revenues as a major product and service category within our Other reportable segment given its distinct markets, and therefore we have elected to report LPD as a reportable segment. The following table presents disaggregated revenue by major product and service categories: ໿ (in thousands) For the Three Months Ended For the Nine Months Ended  2020 2019 2020 2019 CAG segment revenue: CAG Diagnostics recurring revenue: $ 567,416 $ 460,974 $ 1,565,595 $ 1,382,196 IDEXX VetLab consumables 218,605 177,276 603,379 519,646 Rapid assay products 70,593 58,930 192,681 181,966 Reference laboratory diagnostic and consulting services 254,223 204,919 703,300 621,469 CAG Diagnostics services and accessories 23,995 19,849 66,235 59,115 CAG Diagnostics capital - instruments 29,336 32,608 72,040 92,883 Veterinary software, services and diagnostic imaging systems 41,265 39,548 118,478 114,318 CAG segment revenue 638,017 533,130 1,756,113 1,589,397  Water segment revenue 33,272 34,906 95,537 99,980 LPD segment revenue 36,971 31,370 103,369 95,980 Other segment revenue 13,529 5,897 30,698 16,105 Total revenue $ 721,789 $ 605,303 $ 1,985,717 $ 1,801,462 Revenue by principal geographic area, based on customers’ domiciles, was as follows: ໿ (in thousands) For the Three Months Ended For the Nine Months Ended  2020 2019 2020 2019 United States $ 454,836 $ 380,184 $ 1,257,617 $ 1,127,347 Europe, the Middle East and Africa 147,193 122,050 400,928 368,636 Asia Pacific Region 77,401 64,648 212,663 188,756 Canada 28,710 24,334 78,314 75,212 Latin America 13,649 14,087 36,195 41,511 Total $ 721,789 $ 605,303 $ 1,985,717 $ 1,801,462 Costs to Obtain a Contract . We capitalize sales commissions and the related fringe benefits earned by our sales force when considered incremental and recoverable costs of obtaining a contract. Our contracts include performance obligations related to various goods and services, some of which are satisfied at a point in time and others over time. Commission costs related to performance obligations satisfied at a point in time are expensed at the time of sale, which is when revenue is recognized. Commission costs related to long-term service contracts and performance obligations satisfied over time, including extended warranties and SaaS subscriptions, are deferred and recognized on a systematic basis that is consistent with the transfer of the goods or services to which the asset relates. We apply judgment in estimating the amortization period, which ranges from 3 to 7 years, by taking into consideration our customer contract terms, history of renewals, expected length of customer relationship, as well as the useful life of the underlying technology and products. Amortization expense is included in sales and marketing expenses in the accompanying unaudited condensed consolidated statements of income. Deferred commission costs are periodically reviewed for impairment. On December 31, 2019, our deferred commission costs, included within other assets, were $15.6 million, of which approximat ely $1.3 million and $4.0 million of c ommission expense was recognized during the three and nine months ended September 30, 2020, respectively. Furthermore, as a result of commissions related to new extended warranties and SaaS subscriptions, net of subsequent recognition, our deferred commission costs were $16.5 million at September 30, 2020. Impairments of deferred commission costs during the three and nine months ended September 30, 2020, were not material.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS We believe that our acquisitions of businesses and other assets enhance our existing businesses by either expanding our geographic range and customer base or expanding our existing product lines. From time to time we may acquire the assets of small reference labs that we account for as an asset purchase.During the fourth quarter of 2019, we acquired the assets of a multi-site reference laboratory in the Midwest of the U.S. for $50.0 million in cash. This acquisition expands our national reference laboratory presence in the U.S. and was accounted for as a business combination. We finalized the valuation of the assets acquired during the first quarter of 2020. The fair value of the assets acquired consists of $26.9 million in intangible assets, primarily for customer relationships, with a weighted average life of 13.8 years, $0.2 million of tangible assets, and $22.9 million of goodwill, representing synergies within our reference laboratory portfolio. The goodwill is expected to be deductible for income tax purposes.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION The fair value of options, restricted stock units, deferred stock units, and employee stock purchase rights awarded during the three and nine months ended September 30, 2020, totaled $1.3 million and $39.9 million as compared to $3.8 million and $40.1 million for the three and nine months ended September 30, 2019. The total unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding at September 30, 2020, was $64.0 million, which will be recognized over a weighted average period of approximately 1.7 years. During the three and nine months ended September 30, 2020, we recognized expenses of $7.9 million and $23.0 million as compared to $9.4 million and $22.6 million for the three and nine months ended September 30, 2019, related to share-based compensation. We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards. The weighted averages of the valuation assumptions used to determine the fair value of each option award on the date of grant and the weighted average estimated fair values were as follows:  For the Nine Months Ended  2020 2019  Share price at grant $ 290.15 $ 213.35 Expected stock price volatility 27 % 26 % Expected term, in years 6.0 6.0 Risk-free interest rate 1.4 % 2.4 % Weighted average fair value of options granted $ 84.60 $ 64.99

Credit Losses

Credit Losses	9 Months Ended
	Sep. 30, 2020
Credit Loss [Abstract]
Credit Losses	CREDIT LOSSES We are exposed to credit losses primarily through our sales of products and services to our customers. We maintain allowances for credit losses for potentially uncollectible receivables. We base our estimates on a detailed analysis of specific customer situations and a percentage of our accounts receivable by aging category. Historical credit loss experience provides the basis for the estimation of expected credit losses. Adjustments to historical loss information are made for differences in current economic conditions. See Note 2. Accounting Policies, for more information on our adoption of ASU 2016-13 on January 1, 2020, using the modified retrospective transition method. Additional allowances may be required if either the financial condition of our customers was to deteriorate, or a strengthening U.S. dollar impacts the ability of foreign customers to make payments to us on their U.S. dollar-denominated purchases. We monitor our ongoing credit exposure through active review of counterparty balances against contract terms and due dates. Our activities include timely account reconciliations, dispute resolution and payment confirmations. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables. Account balances are charged off against the allowance when we believe it is probable the receivable will not be recovered. We may require collateralized asset support or a prepayment to mitigate credit risk. We do not have any off-balance sheet credit exposure related to our customers. Accounts Receivable The allowance for credit losses associated with accounts receiva ble was $6.6 million an d $3.6 million at September 30, 2020 and December 31, 2019, respectively. Accounts receivable reflected on the balance sheet is net of this reserve. Based on an aging analysis , at September 30, 2020, approximately 88% of our accounts receivable had not yet reached the invoice due date and approximately 12% was considered past due, of which approximately 1.7% was greater than 60 days past due. At December 31, 2019, approximately 84% of our accounts receivable had not yet reached the invoice due date and approximately 16% was considered past due, of which approximately 1.5% was greater than 60 days past due. Contract assets and lease receivables The allowance for credit losses associated with the contract assets and lease receivable s was $3.3 million, a t September 30, 2020. The assets reflected on the balance sheet are net of these reserves. Historically, we have experienced low credit loss rates on our customer commitment programs and lease receivables. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s historical payment experience or, in the case of a new customer, published credit and financial information pertaining to the customer.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2020
Inventory, Net [Abstract]
Inventories	INVENTORIES Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The components of inventories were as follows: (in thousands) September 30, 2020 December 31, 2019  Raw materials $ 46,791 $ 41,202 Work-in-process 19,582 20,077 Finished goods 151,224 133,740 Inventories $ 217,597 $ 195,019

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases	LEASES See Note 7 to the consolidated financial statements in our 2019 Annual Report for additional information regarding leases. Maturities of operating lease liabilities were as follows: (in thousands, except lease term and discount rate) September 30, 2020  2020 (remainder of year) $ 3,824 2021 20,660 2022 17,572 2023 12,453 2024 8,280 Thereafter 39,188 Total lease payments 101,977 Less imputed interest (14,724) Total $ 87,253 Supplemental cash flow information for leases was as follows: (in thousands) For the Nine Months Ended For the Nine Months Ended September 30, 2019  Cash paid for amounts included in the measurement of operating leases liabilities $ 14,619 $ 14,878 Right-of-use assets obtained in exchange for operating lease obligations, net of early lease terminations $ 17,064 $ 7,870

Other Current and Long-Term Ass

Other Current and Long-Term Assets	9 Months Ended
	Sep. 30, 2020
Other Assets, Noncurrent [Abstract]
Other Current and Long-Term Assets	OTHER CURRENT AND LONG-TERM ASSETS Other current assets consisted of the following: ໿ (in thousands) September 30, 2020 December 31, 2019  Customer acquisition costs $ 42,906 $ 39,329 Prepaid expenses 35,966 31,992 Taxes receivable 24,051 20,516 Contract assets, net 20,361 17,659 Deferred sales commissions 5,510 5,202 Other assets 9,108 10,284 Other current assets $ 137,902 $ 124,982 Other long-term assets consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Customer acquisition costs $ 103,075 $ 98,117 Contract assets, net 80,936 66,226 Investment in long-term product supply arrangements 12,599 13,657 Deferred sales commissions 10,993 10,442 Deferred income taxes 8,198 8,100 Taxes receivable 6,329 14,960 Other assets 32,672 28,690 Other long-term assets $ 254,802 $ 240,192

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2020
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	ACCRUED LIABILITIES Accrued liabilities consisted of the following: (in thousands) September 30, 2020 December 31, 2019  Accrued employee compensation and related expenses $ 133,032 $ 127,174 Accrued expenses (Note 16) 100,798 86,296 Accrued customer incentives and refund obligations 71,885 63,079 Accrued taxes 40,013 31,108 Current lease liabilities 16,598 15,281 Accrued liabilities $ 362,326 $ 322,938 ໿ Other long-term liabilities consisted of the following: ໿ (in thousands) September 30, 2020 December 31, 2019 Accrued taxes $ 59,663 $ 67,463 Other accrued long-term expenses 20,001 13,701 Other long-term liabilities $ 79,664 $ 81,164

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	DEBT Senior Notes The following describes all of our currently outstanding unsecured senior notes issued and sold in private placements (collectively, the “Senior Notes”) as of September 30, 2020: (Principal Amount in thousands) Issue Date Due Date Series Principal Amount Coupon Rate Senior Note Agreement (1) 12/11/2013 12/11/2023 2023 Series A Notes $ 75,000 3.94 % NY Life 2013 Note Agreement 12/11/2013 12/11/2025 2025 Series B Notes $ 75,000 4.04 % NY Life 2013 Note Agreement 09/04/2014 09/04/2026 2026 Senior Notes $ 75,000 3.72 % NY Life 2014 Note Agreement 07/21/2014 07/21/2021 2021 Series A Notes $ 50,000 3.32 % Prudential 2015 Amended Agreement 07/21/2014 07/21/2024 2024 Series B Notes $ 75,000 3.76 % Prudential 2015 Amended Agreement 06/18/2015 06/18/2025 2025 Series C Notes € 88,857 1.785 % Prudential 2015 Amended Agreement 02/12/2015 02/12/2022 2022 Series A Notes $ 75,000 3.25 % MetLife 2014 Note Agreement 02/12/2015 02/12/2027 2027 Series B Notes $ 75,000 3.72 % MetLife 2014 Note Agreement 03/14/2019 03/14/2029 2029 Series C Notes $ 100,000 4.19 % MetLife 2014 Note Agreement 04/02/2020 04/02/2030 MetLife 2030 Series D Notes $ 125,000 2.50 % MetLife 2014 Note Agreement 04/14/2020 04/14/2030 Prudential 2030 Series D Notes $ 75,000 2.50 % Prudential 2015 Amended Agreement (1) In each case, as amended. MetLife 2014 Note Agreement On March 23, 2020, we entered into the Second Amendment to the MetLife 2014 Note Agreement (the “MetLife Second Amendment”), in order to (i) increase the facility size from $150 million to $300 million, (ii) extend the facility issuance period to December 20, 2022, (iii) make various implementing and administrative changes in order to facilitate a $125 million notes issuance on April 2, 2020 and (iv) allow the amount available to be issued under the facility to equal $300 million, less the amounts outstanding on 2029 Series C Notes and MetLife 2030 Series D Notes. On April 2, 2020, we issued and sold to MetLife and other purchasers $125 million of our unsecured senior notes (the “MetLife 2030 Series D Notes”) pursuant to the MetLife Second Amendment. The entire outstanding principal balance of the MetLife 2030 Series D Notes is due and payable on April 2, 2030, and the MetLife 2030 Series D Notes bear interest at the rate of 2.50% per annum. We used the proceeds received from the MetLife 2030 Series D Notes for general corporate purposes. Prudential 2015 Amended Agreement On April 10, 2020, we entered into the Second Amendment to the Prudential 2015 Amended Agreement (the “Prudential Second Amendment”), in order to (i) increase the facility size to $425 million, (ii) extend the facility issuance period to April 10, 2023, (iii) make various implementing and administrative changes in order to facilitate a $75 million notes issuance on April 14, 2020, (iv) allow the amount available to be issued under the facility to equal $425 million less the amount of notes outstanding from time to time during the issuance period and (v) modify several defined terms, schedules and covenant baskets in the Prudential 2015 Amended Agreement to create additional operating flexibility, and in particular to align such provisions with similar modifications we made substantially concurrently in our other debt facilities. On April 14, 2020, we issued and sold to Prudential and other purchasers $75 million of our unsecured senior notes (the “Prudential 2030 Series D Notes”) pursuant to the Prudential Second Amendment. The entire outstanding balance of the Prudential 2030 Series D Notes is due and payable on April 14, 2030, and the Prudential 2030 Series D Notes bear interest at the rate of 2.50% per annum. We used the proceeds received from the Prudential 2030 Series D Notes for general corporate purposes. NY Life 2013 and 2014 Note Agreements On April 10, 2020, we amended the NY Life 2013 Note Agreement and the NY Life 2014 Note Agreement by entering into two Amendments to Note Purchase Agreement with New York Life Insurance Company and the other parties thereto, which modified several defined terms, schedules and covenant baskets in the NY Life 2013 Agreement and the NY Life 2014 Note Agreement to create additional operating flexibility, and in particular to align such provisions with similar modifications we made substantially concurrently in our other debt facilities. Senior Note Agreements The Senior Note Agreements contain affirmative, negative, and financial covenants customary for agreements of this type. The negative covenants include restrictions on liens, indebtedness of our subsidiaries, priority indebtedness, fundamental changes, investments, transactions with affiliates, certain restrictive agreements, and violations of laws and regulations. The sole financial covenant is a consolidated leverage ratio test that requires our ratio of debt to earnings before interest, taxes, depreciation, amortization, acquisition-related expense, and share-based compensation, as defined in the Senior Note Agreements, not to exceed 3.5-to-1. At September 30, 2020, we were in compliance with the covenants of the Senior Note Agreements. Should we elect to prepay the Senior Notes, such aggregate prepayment will include the applicable make-whole amount(s), as defined within the applicable Senior Note Agreements. Additionally, in the event of a change in control of the Company or upon the disposition of certain assets of the Company the proceeds of which are not reinvested (as defined in the Senior Note Agreements), we may be required to prepay all or a portion of the Senior Notes. The obligations under the Senior Notes may be accelerated upon the occurrence of an event of default under the applicable Senior Note Agreement, each of which includes customary events of default including payment defaults, defaults in the performance of the affirmative, negative and financial covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency related defaults, defaults relating to judgments, certain events related to employee pension benefit plans under the Employee Retirement Income Security Act of 1974, the failure to pay specified indebtedness and cross-acceleration to specified indebtedness. Credit Facility On April 14, 2020, we, along with IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX Europe B.V., and IDEXX Holding B.V., our wholly-owned subsidiaries (whether directly or indirectly held) (collectively, the “Borrowers”), entered into a third amended and restated credit agreement (the “Credit Agreement”) relating to a three-year unsecured revolving credit facility in the principal amount of $1 billion, among the Borrowers, the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto agent, and the other parties thereto. The Credit Agreement amends and restates that certain second amended and restated credit agreement, dated as of December 4, 2015, (which provided for a $850 million five-year unsecured revolving credit facility) to extend the maturity to April 14, 2023 and to increase the aggregate commitments available for borrowing by the Borrowers to $1 billion with the option to increase the aggregate commitments by $250 million, for an aggregate maximum of up to $1.25 billion, subject to the Borrowers obtaining commitments from existing or new lenders and satisfying other conditions specified in the Credit Agreement.

Repurchases Of Common Stock

Repurchases Of Common Stock	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Repurchases Of Common Stock	REPURCHASES OF COMMON STOCK We primarily acquire shares by repurchases in the open market. However, we also acquire shares that are surrendered by employees in payment for the minimum required statutory withholding taxes due on the vesting of restricted stock units and the settlement of deferred stock units, otherwise referred to herein as employee surrenders. We issue shares of treasury stock upon the vesting of certain restricted stock units and upon the exercise of certain stock options. The number of shares of treasury stock issued during the three and nine months ended September 30, 2020 and 2019 was not material. The following is a summary of our open market common stock repurchases, reported on a trade date basis, and shares acquired through employee surrender: (in thousands, except per share amounts) For the Three Months Ended For the Nine Months Ended  2020 2019 2020 2019  Shares repurchased in the open market — 330 721 683 Shares acquired through employee surrender for statutory tax withholding 1 1 31 38 Total shares repurchased 1 331 752 721  Cost of shares repurchased in the open market $ — $ 91,051 $ 179,623 $ 165,198 Cost of shares for employee surrenders 360 277 9,029 7,849 Total cost of shares $ 360 $ 91,328 $ 188,652 $ 173,047  Average cost per share - open market repurchases $ — $ 275.50 $ 249.20 $ 241.56 Average cost per share - employee surrenders $ 393.12 $ 286.65 $ 292.03 $ 209.20 Average cost per share - total $ 393.12 $ 275.53 $ 250.96 $ 239.87

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES Our effective income tax rate was 10.8% for the three months ended September 30, 2020, as compared to 18.0% for the three months ended September 30, 2019, and 16.0% for the nine months ended September 30, 2020, as compared to 18.5% for the nine months ended September 30, 2019. The decrease in our effective tax rate for the three and nine months ended September 30, 2020, as compared to the same period in the prior year, was primarily driven by higher tax benefits from share-based compensation. The effective tax rate for the three and nine months ended September 30, 2020, differed from the U.S. statutory tax rate of 21% primarily due to tax benefits from share-based compensation.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME The changes in AOCI, net of tax, consisted of the following: For the Nine Months Ended September 30, 2020 Unrealized (Loss) on Cash Flow Hedges, Net of Tax Unrealized (Loss) Gain on (in thousands) Unrealized Gain (Loss) on Investments, Foreign Currency Exchange Contracts Euro-Denominated Notes Cross Currency Swaps Cumulative Translation Total  Balance as of December 31, 2019 $ 110 $ (736) $ 1,396 $ 3,467 $ (50,419) $ (46,182) Other comprehensive (loss) before reclassifications (408) (623) (3,466) (1,339) (7,871) (13,707) Gain reclassified from accumulated other comprehensive income — (2,036) — — — (2,036) Balance as of September 30, 2020 $ (298) $ (3,395) $ (2,070) $ 2,128 $ (58,290) $ (61,925) ໿ For the Nine Months Ended September 30, 2019 Unrealized Gain (Loss) on Cash Flow Hedges, Unrealized (Loss) Gain on (in thousands) Unrealized (Loss) Gain on Investments, Foreign Currency Exchange Contracts Euro-Denominated Notes Cross Currency Swaps Cumulative Translation Total  Balance as of December 31, 2018 $ (157) $ 6,229 $ (394) $ 1,360 $ (48,829) $ (41,791) Other comprehensive (loss) income before reclassifications 295 6,458 3,507 3,993 (12,231) 2,022 Gain reclassified from accumulated other comprehensive income — (5,796) — — — (5,796) Balance as of September 30, 2019 $ 138 $ 6,891 $ 3,113 $ 5,353 $ (61,060) $ (45,565) The following tables present components and amounts reclassified out of AOCI to net income: (in thousands) Affected Line Item in the Statements of Income Amounts Reclassified from AOCI For the Three Months Ended September 30,  2020 2019 Gain (loss) on derivative instruments classified as cash flow hedges included in net income: Foreign currency exchange contracts Cost of revenue $ (591) $ 3,171  Tax expense (benefit) (53) 688  Gain (loss), net of tax $ (538) $ 2,483 (in thousands) Affected Line Item in the Statements of Income Amounts Reclassified from AOCI For the Nine Months Ended September 30,  2020 2019 Gain on derivative instruments classified as cash flow hedges included in net income: Foreign currency exchange contracts Cost of revenue $ 2,562 $ 7,091  Tax expense 526 1,295  Gain, net of tax $ 2,036 $ 5,796

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE Basic earnings per share is computed by dividing net income attributable to our stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options and the total unrecognized compensation expense for unvested share-based compensation awards, would be used to purchase our common stock at the average market price during the period. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent. See Note 5 to the consolidated financial statements in our 2019 Annual Report for additional information regarding deferred stock units. The following is a reconciliation of weighted average shares outstanding for basic and diluted earnings per share: (in thousands) For the Three Months Ended For the Nine Months Ended  2020 2019 2020 2019  Shares outstanding for basic earnings per share 85,314 86,198 85,293 86,206  Shares outstanding for diluted earnings per share: Shares outstanding for basic earnings per share 85,314 86,198 85,293 86,206 Dilutive effect of share-based payment awards 1,376 1,469 1,342 1,427  86,690 87,667 86,635 87,633 ໿ ໿ Certain awards and options to acquire shares have been excluded from the calculation of shares outstanding for diluted earnings per share because they were anti-dilutive. The following table presents information concerning those anti-dilutive awards and options: (in thousands) For the Three Months Ended For the Nine Months Ended  2020 2019 2020 2019  Weighted average number of shares underlying anti-dilutive awards 1 — — — Weighted average number of shares underlying anti-dilutive options 10 29 236 247

Commitments, Contingencies and

Commitments, Contingencies and Guarantees	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Guarantees	COMMITMENTS, CONTINGENCIES AND GUARANTEES Commitments See “Note 8. Leases”, for more information regarding our lease commitments. Contingencies and Guarantees We are subject to claims that may arise in the ordinary course of business, including with respect to actual and threatened litigation and other matters. We accrue for loss contingencies when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. However, the results of legal actions cannot be predicted with certainty, and therefore our actual losses with respect to these contingencies could be higher and lower than our accruals. Except for the litigation matter described below, at September 30, 2020, our accruals with respect to actual and threatened litigation were not material. We are a defendant in an ongoing litigation matter involving an alleged breach of contract for underpayment of royalty payments made from 2004 through 2017 under an expired patent license agreement. The plaintiff has asserted a claim of approximately $50 million, inclusive of interest, alleging that the incorrect royalty provision was applied to certain licensed products and services throughout the agreement term and that royalties were also due on non-licensed diagnostic services that were provided concurrently with licensed services. The trial court has ruled in favor of the plaintiff in this matter and we are appealing the judgment and continue to vigorously defend ourselves against the plaintiff’s allegations. While we believe the claim is without merit, litigation is inherently unpredictable and there can be no assurance that we will prevail in this matter. We have established an accrual of $27.5 million related to this ongoing matter, which represents the amount of a possible loss that we have determined to be probable and estimable. The actual cost of resolving this matter may be higher or lower than the amount we have accrued. From time to time, we have received notices alleging that our products infringe third-party proprietary rights, although we are not aware of any pending litigation with respect to such claims. Patent litigation frequently is complex and expensive, and the outcome of patent litigation can be difficult to predict. There can be no assurance that we will prevail in any infringement proceedings that may be commenced against us. If we lose any such litigation, we may be stopped from selling certain products and/or we may be required to pay damages as a result of the litigation. Excluding the litigation described above, we have had no significant changes to our contingencies and guarantees discussed in Note 15 to the consolidated financial statements in our 2019 Annual Report.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Reporting	SEGMENT REPORTING Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. Our reportable segments include diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality products (“Water”) and diagnostic products and services for livestock and poultry health and to ensure the quality and safety of milk and improve dairy efficiency, which we refer to as Livestock, Poultry and Dairy (“LPD”). Although our LPD segment does not meet the quantitative thresholds to be reported as a separate segment, we believe it is important to disaggregate these revenues as a major product and service category within our Other reportable segment given its distinct markets, and therefore we have elected to report LPD as a reportable segment. Our Other operating segment combines and presents products for the human medical diagnostics (“OPTI Medical”) market with our out-licensing arrangements. Assets are not allocated to segments for internal reporting purposes. Effective January 1, 2020, we modified our management reporting to the Chief Operating Decision Maker to provide a more comprehensive view of the performance of our operating segments by including costs that previously were not allocated to our segments. Prior to January 1, 2020, certain costs were not allocated to our operating segments and were instead reported under the caption “Unallocated Amounts”. These costs primarily consist of our R&D function, regional or country expenses and unusual items. Corporate support function costs (such as information technology, facilities, human resources, finance and legal), health benefits and incentive compensation were charged to our business segments at pre-determined budgeted amounts or rates. Beginning January 1, 2020, the segments reflect these actual costs allocated to the segment based on various allocation methods, including revenue and headcount. Foreign exchange losses on settlements of foreign currency denominated transactions are not allocated to our operating segments and are instead reported within our Other reporting segment. The following table reflects adjustments to previously reported costs in our Unallocated segment, that are now allocated to our CAG, Water, LPD and Other segments for the three and nine months ended September 30, 2019, respectively: (in thousands) Three Months Ended September 30, 2019 CAG Water LPD Other Unallocated Cost of sales $ (428) $ (19) $ (24) $ (10) $ 481 Gross profit 428 19 24 10 (481) Operating Expenses: Sales and marketing $ 211 $ 9 $ 12 $ — $ (232) General and administrative 2,472 105 131 1,058 (3,766) Research and development 4,544 20 25 — (4,589) Total operating expenses $ 7,227 $ 134 $ 168 $ 1,058 $ (8,587) Income from operations $ (6,799) $ (115) $ (144) $ (1,048) $ 8,106 (in thousands) Nine Months Ended September 30, 2019 CAG Water LPD Other Unallocated Cost of sales $ (266) $ (12) $ (15) $ (6) $ 299 Gross profit 266 12 15 6 (299) Operating Expenses: Sales and marketing $ 322 $ 14 $ 18 $ — $ (354) General and administrative 1,377 (114) (122) 2,222 (3,363) Research and development 12,062 39 49 — (12,150) Total operating expenses $ 13,761 $ (61) $ (55) $ 2,222 $ (15,867) Income from operations $ (13,495) $ 73 $ 70 $ (2,216) $ 15,568 The following is a summary of segment performance: For the Three Months Ended September 30, CAG Water LPD Other Consolidated Total 2020 Revenue $ 638,017 $ 33,272 $ 36,971 $ 13,529 $ 721,789 Income from operations $ 139,434 $ 15,243 $ 10,505 $ 6,674 $ 171,856 Interest expense, net (7,902) Income before provision for income taxes 163,954 Provision for income taxes 17,633 Net income 146,321 Less: Net income attributable to noncontrolling interest 102 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 146,219 2019 Revenue $ 533,130 $ 34,906 $ 31,370 $ 5,897 $ 605,303 Income from operations $ 117,691 $ 16,930 $ 4,850 $ 331 $ 139,802 Interest expense, net (7,004) Income before provision for income taxes 132,798 Provision for income taxes 23,960 Net income 108,838 Less: Net income attributable to noncontrolling interest 1 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 108,837 (in thousands) For the Nine Months Ended September 30,  CAG Water LPD Other Consolidated Total 2020 Revenue $ 1,756,113 $ 95,537 $ 103,369 $ 30,698 $ 1,985,717  Income from operations $ 426,062 $ 43,383 $ 28,417 $ 11,567 $ 509,429 Interest expense, net (24,880) Income before provision for income taxes 484,549 Provision for income taxes 77,376 Net income 407,173 Less: Net income attributable to noncontrolling interest 187 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 406,986  2019 Revenue $ 1,589,397 $ 99,980 $ 95,980 $ 16,105 $ 1,801,462  Income from operations $ 370,600 $ 47,467 $ 17,707 $ 1,441 $ 437,215 Interest expense, net (23,503) Income before provision for income taxes 413,712 Provision for income taxes 76,464 Net income 337,248 Less: Net income attributable to noncontrolling interest 24 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 337,224

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. We have certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a non-recurring basis and certain financial assets and liabilities that are not measured at fair value in our unaudited condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows: Level 1 Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the three and nine months ended September 30, 2020. Our cross currency swap contracts are measured at fair value on a recurring basis in our accompanying unaudited condensed consolidated balance sheets. We measure the fair value of our cross currency swap contracts classified as derivative instruments using prevailing market conditions as of the close of business on each balance sheet date. The product of this calculation is then adjusted for counterparty risk. Our foreign currency exchange contracts are measured at fair value on a recurring basis in our accompanying unaudited condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk. The amounts outstanding under our unsecured revolving credit facility (“Credit Facility” or “line of credit”) and senior notes (“long-term debt”) are measured at carrying value in our unaudited condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and long-term debt are valued using Level 2 inputs. The estimated fai r value of our Credit Facility approximates its carrying value. The estimated fair value and carrying value of our long-term debt were $998.5 million and $904.0 million, respectively, as of September 30, 2020, and $753.6 million and $699.4 million, respectively, as of December 31, 2019. The following tables set forth our assets and liabilities that were measured at fair value on a recurring basis by level within the fair value hierarchy: (in thousands) As of September 30, 2020 Quoted Prices Significant Significant Balance at September 30, 2020  Assets Money market funds (1) $ 76 $ — $ — $ 76 Equity mutual funds (2) $ 1,182 $ — $ — $ 1,182 Cross currency swaps (3) $ — $ 2,797 $ — $ 2,797 Foreign currency exchange contracts (3) $ — $ 609 $ — $ 609 Liabilities Foreign currency exchange contracts (3) $ — $ 4,821 $ — $ 4,821 Deferred compensation (4) $ 1,182 $ — $ — $ 1,182 (in thousands) As of December 31, 2019 Quoted Prices Significant Significant Balance at December 31, 2019  Assets Money market funds (1) $ 71 $ — $ — $ 71 Equity mutual funds (2) $ 1,676 $ — $ — $ 1,676 Cross currency swaps (3) $ — $ 4,559 $ — $ 4,559 Foreign currency exchange contracts (3) $ — $ 1,791 $ — $ 1,791 Liabilities Foreign currency exchange contracts (3) $ — $ 2,886 $ — $ 2,886 Deferred compensation (4) $ 1,676 $ — $ — $ 1,676 (1) Money market funds with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of September 30, 2020 and December 31, 2019, consisted of demand deposits. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets. See footnote (4) below for a discussion of the related deferred compensation liability. (3) Cross currency swaps and foreign currency exchange contracts are included within other current assets, other long-term assets, accrued liabilities, or other long-term liabilities depending on the gain (loss) position and anticipated settlement date. (4) A deferred compensation plan assumed as part of a previous business combination is included within accrued liabilities and other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in footnote (2) above. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate carrying value due to their short maturity.

Hedging Instruments

Hedging Instruments	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Hedging Instruments	HEDGING INSTRUMENTS Disclosure within this note is presented to provide transparency about how and why we use derivative and non-derivative instruments (collectively “hedging instruments”), how the instruments and related hedged items are accounted for, and how the instruments and related hedged items affect our financial position, results of operations and cash flows. We are exposed to certain risks related to our ongoing business operations. The primary risk that we currently manage by using hedging instruments is foreign currency exchange risk. We may also enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts, cross currency swaps or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures, including net investments in certain foreign subsidiaries. The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in the euro, British pound, Japanese yen, Canadian dollar, and Australian dollar. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign currency exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in transactions involving derivative instruments for purposes other than risk management. Our accounting policies for these contracts are based on the designation of such instruments as hedging transactions. We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. Instruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cash flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, changes in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earnings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See “Note 14. Accumulated Other Comprehensive Income” for further information regarding the effect of hedging instruments on our unaudited condensed consolidated statements of income for the three and nine months ended September 30, 2020 and 2019. We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the unaudited condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged. Cash Flow Hedges We have designated our foreign currency exchange contracts as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment. We did not de-designate any instruments from hedge accounting treatment during either the three and nine months ended September 30, 2020 or 2019. At September 30, 2020, the estimated amount of net losses, net of tax, which are expected to be reclassified out of AOCI and into earnings within the next 12 months, is $2.5 million if exchange rates do not fluctuate from the levels at September 30, 2020. We hedge approximately 85% of the estimated exposure from intercompany product purchases and sales denominated in the euro, British pound, Canadian dollar, Japanese yen, and Australian dollar. We have additional unhedged foreign currency exposures related to foreign services and emerging markets where it is not practical to hedge. We primarily utilize foreign currency exchange contracts with durations of less than 24 months. Quarterly, we enter into contracts to hedge incremental portions of anticipated foreign currency transactions for the current and following year. As a result, our risk with respect to foreign currency exchange rate fluctuations and the notional value of foreign currency exchange contracts may vary throughout the year. The U.S. dollar is the currency purchased or sold in all of our foreign currency exchange contracts. The notional amount of foreign currency exchange contracts to hedge forecasted intercompany inventory purchases and sales totaled $208.6 million and $210.9 million at September 30, 2020 and December 31, 2019, respectively. The following tables present the effect of cash flow hedge accounting on our unaudited condensed consolidated statements of income and comprehensive income, and provide information regarding the location and amounts of pretax gains or losses of derivatives: (in thousands) Three Months Ended September 30,  2020 2019 Financial statement line items in which effects of cash flow hedges are recorded Cost of revenue $ 299,183 $ 260,353 Foreign exchange contracts Amount of gain (loss) reclassified from accumulated other comprehensive income into income $ (591) $ 3,171 (in thousands) Nine Months Ended September 30,  2020 2019 Financial statement line items in which effects of cash flow hedges are recorded Cost of revenue $ 824,179 $ 767,062 Foreign exchange contracts Amount of gain reclassified from accumulated other comprehensive income into income $ 2,562 $ 7,091 Net Investment Hedges In June 2015, we issued and sold through a private placement an aggregate principal amount of €88.9 million in euro-denominated 1.785% Series C Senior Notes due June 18, 2025. We have designated these euro-denominated notes as a hedge of our euro net investment in certain foreign subsidiaries to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates in the euro relative to the U.S. dollar. As a result of this designation, gains and losses from the change in translated U.S. dollar value of these euro-denominated notes are recorded in AOCI rather than to earnings. We recorded losses of $2.8 million and $3.5 million, net of tax, within AOCI as a result of this net investment hedge for the three and nine months ended September 30, 2020, respectively, and gains of $3.0 million and $3.5 million for the three and nine months ended September 30, 2019. The related cumulative unrealized gain recorded at September 30, 2020, will not be reclassified in earnings until the complete or substantially complete liquidation of the net investment in the hedged foreign operations or a portion of the hedge no longer qualifies for hedge accounting treatment. See Note 12 to the consolidated financial statements included in our 2019 Annual Report for further information regarding the issuance of these euro-denominated notes. We have entered into several cross currency swap contracts as a hedge of our net investment in foreign operations to offset foreign currency translation gains and losses on the net investment. These cross currency swaps have maturity dates beginning on June 30, 2023, through June 18, 2025. At maturity of the cross currency swap contracts, we will deliver the notional amount of €90.0 million and will receive approximately $104.5 million from the counterparties on June 30, 2023, and we will deliver the notional amount of €10 million and will receive approximately $11.4 million from the counterparties on June 18, 2025. The change in fair value of the cross currency swap contracts are recorded in AOCI and will be reclassified to earnings when the foreign subsidiaries are sold or substantially liquidate d. During the three and nine months ended September 30, 2020, we recorded losses of $3.9 million and $1.3 million, net of tax, within AOCI as a result of these net investment hedges, respectively, and gains of $3.1 million and $4.0 million during the three and nine months ended September 30, 2019. We will receive quarterly interest payments from the counterparties based on a fixed interest rate until maturity of the cross currency swaps. This interest rate component is excluded from the assessment of hedge effectiveness and, thus is recognized as a reduction to interest expense over the life of the hedge instrument. We recognized ap proximately $0.7 million and $2.0 million related to the excluded component as a reduction of interest expense for the three and nine months ended September 30, 2020, respectively, and $0.6 million and $1.7 million for the three and nine months ended September 30, 2019, respectively. Fair Values of Hedging Instruments Designated as Hedges in Consolidated Balance Sheets The fair values of hedging instruments and their respective classification on our unaudited condensed consolidated balance sheets and amounts subject to offset under master netting arrangements consisted of the following derivative instruments, unless otherwise noted: (in thousands) Hedging Assets  September 30, 2020 December 31, 2019  Derivatives and non-derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Other current assets $ 519 $ 1,791 Cross currency swaps Other long-term assets 2,797 4,559 Foreign currency exchange contracts Other long-term assets 90 — Total derivative instruments presented as hedge instruments on the balance sheet 3,406 6,350 Gross amounts subject to master netting arrangements not offset on the balance sheet (609) (1,354) Net amount $ 2,797 $ 4,996 ໿ (in thousands) Hedging Liabilities  September 30, 2020 December 31, 2019  Derivatives and non-derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Accrued liabilities $ 3,631 $ 2,886 Foreign currency exchange contracts Other long-term liabilities 1,190 — Total derivative instruments presented as cash flow hedges on the balance sheet 4,821 2,886 Non-derivative foreign currency denominated debt designated as net investment hedge on the balance sheet (1) Long-term debt 103,980 99,422 Total hedging instruments presented on the balance sheet 108,801 102,308 Gross amounts subject to master netting arrangements not offset on the balance sheet (609) (1,354) Net amount $ 108,192 $ 100,954 (1) Amounts represent reported carrying amounts of our foreign currency denominated debt. See “Note 18. Fair Value Measurements” for information regarding the fair value of our long-term debt.

Accounting Policies (Policies)

Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
New Accounting Pronouncements Adopted and Not Yet Adopted	New Accounting Pronouncements Adopted Effective January 1, 2020, we adopted ASU 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosure requirements on fair value measurements under ASC Topic No. 820, Fair Value Measurement, as amended (“ASC 820”). ASU 2018-13 removes (a) the prior requirement to disclose the amount and reason for transfers between Level 1 and Level 2 of the fair value hierarchy contained in ASC 820, (b) the policy for timing of transfers between levels, and (c) the valuation processes used for Level 3 fair value measurements. ASU 2018-13 also adds, among other things, a requirement to disclose the range and weighted average of significant unobservable inputs used in Level 3 fair value measurements. The adoption did not have a material impact on our consolidated financial statements. Effective January 1, 2020, we adopted ASU 2016-13 New Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” The new guidance is intended to simplify the accounting for income taxes by removing certain exceptions and by updating accounting requirements around goodwill recognized for tax purposes and the allocation of current and deferred tax expense among legal entities, among other minor changes. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. We do not expect the adoption of ASU 2019-12 to have a material impact on our consolidated financial statements. In March 2020, the FASB issued ASU 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” ASU 2020-04 is intended to provide optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the discontinuation of the London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued. The relief offered by this guidance, if adopted, is availa ble to companies for the period March 12, 2020 through December 31, 2022. We do not expect the discontinuation of LIBOR to h ave a material impact on our consolidated financial statements.
Share-based Compensation	We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards.
Credit Losses	We are exposed to credit losses primarily through our sales of products and services to our customers. We maintain allowances for credit losses for potentially uncollectible receivables. We base our estimates on a detailed analysis of specific customer situations and a percentage of our accounts receivable by aging category. Historical credit loss experience provides the basis for the estimation of expected credit losses. Adjustments to historical loss information are made for differences in current economic conditions. See Note 2. Accounting Policies, for more information on our adoption of ASU 2016-13 on January 1, 2020, using the modified retrospective transition method. Additional allowances may be required if either the financial condition of our customers was to deteriorate, or a strengthening U.S. dollar impacts the ability of foreign customers to make payments to us on their U.S. dollar-denominated purchases. We monitor our ongoing credit exposure through active review of counterparty balances against contract terms and due dates. Our activities include timely account reconciliations, dispute resolution and payment confirmations. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables. Account balances are charged off against the allowance when we believe it is probable the receivable will not be recovered. We may require collateralized asset support or a prepayment to mitigate credit risk. We do not have any off-balance sheet credit exposure related to our customers.
Inventories	Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.
Earnings Per Share	Basic earnings per share is computed by dividing net income attributable to our stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options and the total unrecognized compensation expense for unvested share-based compensation awards, would be used to purchase our common stock at the average market price during the period. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent.
Fair Value Measurements	U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. We have certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a non-recurring basis and certain financial assets and liabilities that are not measured at fair value in our unaudited condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows: Level 1 Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the three and nine months ended September 30, 2020. Our cross currency swap contracts are measured at fair value on a recurring basis in our accompanying unaudited condensed consolidated balance sheets. We measure the fair value of our cross currency swap contracts classified as derivative instruments using prevailing market conditions as of the close of business on each balance sheet date. The product of this calculation is then adjusted for counterparty risk. Our foreign currency exchange contracts are measured at fair value on a recurring basis in our accompanying unaudited condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk.
Derivatives	We are exposed to certain risks related to our ongoing business operations. The primary risk that we currently manage by using hedging instruments is foreign currency exchange risk. We may also enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts, cross currency swaps or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures, including net investments in certain foreign subsidiaries. The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in the euro, British pound, Japanese yen, Canadian dollar, and Australian dollar. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign currency exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in transactions involving derivative instruments for purposes other than risk management. Our accounting policies for these contracts are based on the designation of such instruments as hedging transactions. We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. Instruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cash flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, changes in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earnings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See “Note 14. Accumulated Other Comprehensive Income” for further information regarding the effect of hedging instruments on our unaudited condensed consolidated statements of income for the three and nine months ended September 30, 2020 and 2019. We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the unaudited condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged. Cash Flow Hedges

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue	The following table presents disaggregated revenue by major product and service categories: ໿ (in thousands) For the Three Months Ended For the Nine Months Ended  2020 2019 2020 2019 CAG segment revenue: CAG Diagnostics recurring revenue: $ 567,416 $ 460,974 $ 1,565,595 $ 1,382,196 IDEXX VetLab consumables 218,605 177,276 603,379 519,646 Rapid assay products 70,593 58,930 192,681 181,966 Reference laboratory diagnostic and consulting services 254,223 204,919 703,300 621,469 CAG Diagnostics services and accessories 23,995 19,849 66,235 59,115 CAG Diagnostics capital - instruments 29,336 32,608 72,040 92,883 Veterinary software, services and diagnostic imaging systems 41,265 39,548 118,478 114,318 CAG segment revenue 638,017 533,130 1,756,113 1,589,397  Water segment revenue 33,272 34,906 95,537 99,980 LPD segment revenue 36,971 31,370 103,369 95,980 Other segment revenue 13,529 5,897 30,698 16,105 Total revenue $ 721,789 $ 605,303 $ 1,985,717 $ 1,801,462 Revenue by principal geographic area, based on customers’ domiciles, was as follows: ໿ (in thousands) For the Three Months Ended For the Nine Months Ended  2020 2019 2020 2019 United States $ 454,836 $ 380,184 $ 1,257,617 $ 1,127,347 Europe, the Middle East and Africa 147,193 122,050 400,928 368,636 Asia Pacific Region 77,401 64,648 212,663 188,756 Canada 28,710 24,334 78,314 75,212 Latin America 13,649 14,087 36,195 41,511 Total $ 721,789 $ 605,303 $ 1,985,717 $ 1,801,462

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of weighted averages of the assumptions used in estimating the fair value of stock option awards	The weighted averages of the valuation assumptions used to determine the fair value of each option award on the date of grant and the weighted average estimated fair values were as follows:  For the Nine Months Ended  2020 2019  Share price at grant $ 290.15 $ 213.35 Expected stock price volatility 27 % 26 % Expected term, in years 6.0 6.0 Risk-free interest rate 1.4 % 2.4 % Weighted average fair value of options granted $ 84.60 $ 64.99

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory, Net [Abstract]
Schedule of components of inventories	The components of inventories were as follows: (in thousands) September 30, 2020 December 31, 2019  Raw materials $ 46,791 $ 41,202 Work-in-process 19,582 20,077 Finished goods 151,224 133,740 Inventories $ 217,597 $ 195,019

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Maturities of operating lease liabilities	Maturities of operating lease liabilities were as follows: (in thousands, except lease term and discount rate) September 30, 2020  2020 (remainder of year) $ 3,824 2021 20,660 2022 17,572 2023 12,453 2024 8,280 Thereafter 39,188 Total lease payments 101,977 Less imputed interest (14,724) Total $ 87,253
Lease and supplemental cash flow information	Supplemental cash flow information for leases was as follows: (in thousands) For the Nine Months Ended For the Nine Months Ended September 30, 2019  Cash paid for amounts included in the measurement of operating leases liabilities $ 14,619 $ 14,878 Right-of-use assets obtained in exchange for operating lease obligations, net of early lease terminations $ 17,064 $ 7,870

Other Current and Long-Term A_2

Other Current and Long-Term Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Other Assets, Noncurrent [Abstract]
Schedule of other current assets	Other current assets consisted of the following: ໿ (in thousands) September 30, 2020 December 31, 2019  Customer acquisition costs $ 42,906 $ 39,329 Prepaid expenses 35,966 31,992 Taxes receivable 24,051 20,516 Contract assets, net 20,361 17,659 Deferred sales commissions 5,510 5,202 Other assets 9,108 10,284 Other current assets $ 137,902 $ 124,982
Schedule of other long-term assets	Other long-term assets consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Customer acquisition costs $ 103,075 $ 98,117 Contract assets, net 80,936 66,226 Investment in long-term product supply arrangements 12,599 13,657 Deferred sales commissions 10,993 10,442 Deferred income taxes 8,198 8,100 Taxes receivable 6,329 14,960 Other assets 32,672 28,690 Other long-term assets $ 254,802 $ 240,192

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Accrued Liabilities, Current [Abstract]
Schedule of accrued liabilities	Accrued liabilities consisted of the following: (in thousands) September 30, 2020 December 31, 2019  Accrued employee compensation and related expenses $ 133,032 $ 127,174 Accrued expenses (Note 16) 100,798 86,296 Accrued customer incentives and refund obligations 71,885 63,079 Accrued taxes 40,013 31,108 Current lease liabilities 16,598 15,281 Accrued liabilities $ 362,326 $ 322,938
Schedule of other long-term liabilities	Other long-term liabilities consisted of the following: ໿ (in thousands) September 30, 2020 December 31, 2019 Accrued taxes $ 59,663 $ 67,463 Other accrued long-term expenses 20,001 13,701 Other long-term liabilities $ 79,664 $ 81,164

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of long-term debt instruments	The following describes all of our currently outstanding unsecured senior notes issued and sold in private placements (collectively, the “Senior Notes”) as of September 30, 2020: (Principal Amount in thousands) Issue Date Due Date Series Principal Amount Coupon Rate Senior Note Agreement (1) 12/11/2013 12/11/2023 2023 Series A Notes $ 75,000 3.94 % NY Life 2013 Note Agreement 12/11/2013 12/11/2025 2025 Series B Notes $ 75,000 4.04 % NY Life 2013 Note Agreement 09/04/2014 09/04/2026 2026 Senior Notes $ 75,000 3.72 % NY Life 2014 Note Agreement 07/21/2014 07/21/2021 2021 Series A Notes $ 50,000 3.32 % Prudential 2015 Amended Agreement 07/21/2014 07/21/2024 2024 Series B Notes $ 75,000 3.76 % Prudential 2015 Amended Agreement 06/18/2015 06/18/2025 2025 Series C Notes € 88,857 1.785 % Prudential 2015 Amended Agreement 02/12/2015 02/12/2022 2022 Series A Notes $ 75,000 3.25 % MetLife 2014 Note Agreement 02/12/2015 02/12/2027 2027 Series B Notes $ 75,000 3.72 % MetLife 2014 Note Agreement 03/14/2019 03/14/2029 2029 Series C Notes $ 100,000 4.19 % MetLife 2014 Note Agreement 04/02/2020 04/02/2030 MetLife 2030 Series D Notes $ 125,000 2.50 % MetLife 2014 Note Agreement 04/14/2020 04/14/2030 Prudential 2030 Series D Notes $ 75,000 2.50 % Prudential 2015 Amended Agreement (1) In each case, as amended.

Repurchases of Common Stock (Ta

Repurchases of Common Stock (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Schedule of common stock repurchases	The following is a summary of our open market common stock repurchases, reported on a trade date basis, and shares acquired through employee surrender: (in thousands, except per share amounts) For the Three Months Ended For the Nine Months Ended  2020 2019 2020 2019  Shares repurchased in the open market — 330 721 683 Shares acquired through employee surrender for statutory tax withholding 1 1 31 38 Total shares repurchased 1 331 752 721  Cost of shares repurchased in the open market $ — $ 91,051 $ 179,623 $ 165,198 Cost of shares for employee surrenders 360 277 9,029 7,849 Total cost of shares $ 360 $ 91,328 $ 188,652 $ 173,047  Average cost per share - open market repurchases $ — $ 275.50 $ 249.20 $ 241.56 Average cost per share - employee surrenders $ 393.12 $ 286.65 $ 292.03 $ 209.20 Average cost per share - total $ 393.12 $ 275.53 $ 250.96 $ 239.87

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Schedule of accumulated other comprehensive income	The changes in AOCI, net of tax, consisted of the following: For the Nine Months Ended September 30, 2020 Unrealized (Loss) on Cash Flow Hedges, Net of Tax Unrealized (Loss) Gain on (in thousands) Unrealized Gain (Loss) on Investments, Foreign Currency Exchange Contracts Euro-Denominated Notes Cross Currency Swaps Cumulative Translation Total  Balance as of December 31, 2019 $ 110 $ (736) $ 1,396 $ 3,467 $ (50,419) $ (46,182) Other comprehensive (loss) before reclassifications (408) (623) (3,466) (1,339) (7,871) (13,707) Gain reclassified from accumulated other comprehensive income — (2,036) — — — (2,036) Balance as of September 30, 2020 $ (298) $ (3,395) $ (2,070) $ 2,128 $ (58,290) $ (61,925) ໿ For the Nine Months Ended September 30, 2019 Unrealized Gain (Loss) on Cash Flow Hedges, Unrealized (Loss) Gain on (in thousands) Unrealized (Loss) Gain on Investments, Foreign Currency Exchange Contracts Euro-Denominated Notes Cross Currency Swaps Cumulative Translation Total  Balance as of December 31, 2018 $ (157) $ 6,229 $ (394) $ 1,360 $ (48,829) $ (41,791) Other comprehensive (loss) income before reclassifications 295 6,458 3,507 3,993 (12,231) 2,022 Gain reclassified from accumulated other comprehensive income — (5,796) — — — (5,796) Balance as of September 30, 2019 $ 138 $ 6,891 $ 3,113 $ 5,353 $ (61,060) $ (45,565)
Summary of reclassifications out of other comprehensive income	The following tables present components and amounts reclassified out of AOCI to net income: (in thousands) Affected Line Item in the Statements of Income Amounts Reclassified from AOCI For the Three Months Ended September 30,  2020 2019 Gain (loss) on derivative instruments classified as cash flow hedges included in net income: Foreign currency exchange contracts Cost of revenue $ (591) $ 3,171  Tax expense (benefit) (53) 688  Gain (loss), net of tax $ (538) $ 2,483 (in thousands) Affected Line Item in the Statements of Income Amounts Reclassified from AOCI For the Nine Months Ended September 30,  2020 2019 Gain on derivative instruments classified as cash flow hedges included in net income: Foreign currency exchange contracts Cost of revenue $ 2,562 $ 7,091  Tax expense 526 1,295  Gain, net of tax $ 2,036 $ 5,796

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of reconciliation of shares outstanding for basic and diluted earnings per share	The following is a reconciliation of weighted average shares outstanding for basic and diluted earnings per share: (in thousands) For the Three Months Ended For the Nine Months Ended  2020 2019 2020 2019  Shares outstanding for basic earnings per share 85,314 86,198 85,293 86,206  Shares outstanding for diluted earnings per share: Shares outstanding for basic earnings per share 85,314 86,198 85,293 86,206 Dilutive effect of share-based payment awards 1,376 1,469 1,342 1,427  86,690 87,667 86,635 87,633
Schedule of number of anti-dilutive stock options	The following table presents information concerning those anti-dilutive awards and options: (in thousands) For the Three Months Ended For the Nine Months Ended  2020 2019 2020 2019  Weighted average number of shares underlying anti-dilutive awards 1 — — — Weighted average number of shares underlying anti-dilutive options 10 29 236 247

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Summary of segment performance	The following table reflects adjustments to previously reported costs in our Unallocated segment, that are now allocated to our CAG, Water, LPD and Other segments for the three and nine months ended September 30, 2019, respectively: (in thousands) Three Months Ended September 30, 2019 CAG Water LPD Other Unallocated Cost of sales $ (428) $ (19) $ (24) $ (10) $ 481 Gross profit 428 19 24 10 (481) Operating Expenses: Sales and marketing $ 211 $ 9 $ 12 $ — $ (232) General and administrative 2,472 105 131 1,058 (3,766) Research and development 4,544 20 25 — (4,589) Total operating expenses $ 7,227 $ 134 $ 168 $ 1,058 $ (8,587) Income from operations $ (6,799) $ (115) $ (144) $ (1,048) $ 8,106 (in thousands) Nine Months Ended September 30, 2019 CAG Water LPD Other Unallocated Cost of sales $ (266) $ (12) $ (15) $ (6) $ 299 Gross profit 266 12 15 6 (299) Operating Expenses: Sales and marketing $ 322 $ 14 $ 18 $ — $ (354) General and administrative 1,377 (114) (122) 2,222 (3,363) Research and development 12,062 39 49 — (12,150) Total operating expenses $ 13,761 $ (61) $ (55) $ 2,222 $ (15,867) Income from operations $ (13,495) $ 73 $ 70 $ (2,216) $ 15,568 The following is a summary of segment performance: For the Three Months Ended September 30, CAG Water LPD Other Consolidated Total 2020 Revenue $ 638,017 $ 33,272 $ 36,971 $ 13,529 $ 721,789 Income from operations $ 139,434 $ 15,243 $ 10,505 $ 6,674 $ 171,856 Interest expense, net (7,902) Income before provision for income taxes 163,954 Provision for income taxes 17,633 Net income 146,321 Less: Net income attributable to noncontrolling interest 102 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 146,219 2019 Revenue $ 533,130 $ 34,906 $ 31,370 $ 5,897 $ 605,303 Income from operations $ 117,691 $ 16,930 $ 4,850 $ 331 $ 139,802 Interest expense, net (7,004) Income before provision for income taxes 132,798 Provision for income taxes 23,960 Net income 108,838 Less: Net income attributable to noncontrolling interest 1 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 108,837 (in thousands) For the Nine Months Ended September 30,  CAG Water LPD Other Consolidated Total 2020 Revenue $ 1,756,113 $ 95,537 $ 103,369 $ 30,698 $ 1,985,717  Income from operations $ 426,062 $ 43,383 $ 28,417 $ 11,567 $ 509,429 Interest expense, net (24,880) Income before provision for income taxes 484,549 Provision for income taxes 77,376 Net income 407,173 Less: Net income attributable to noncontrolling interest 187 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 406,986  2019 Revenue $ 1,589,397 $ 99,980 $ 95,980 $ 16,105 $ 1,801,462  Income from operations $ 370,600 $ 47,467 $ 17,707 $ 1,441 $ 437,215 Interest expense, net (23,503) Income before provision for income taxes 413,712 Provision for income taxes 76,464 Net income 337,248 Less: Net income attributable to noncontrolling interest 24 Net income attributable to IDEXX Laboratories, Inc. stockholders $ 337,224

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of fair value of assets and liabilities measured on recurring basis	The following tables set forth our assets and liabilities that were measured at fair value on a recurring basis by level within the fair value hierarchy: (in thousands) As of September 30, 2020 Quoted Prices Significant Significant Balance at September 30, 2020  Assets Money market funds (1) $ 76 $ — $ — $ 76 Equity mutual funds (2) $ 1,182 $ — $ — $ 1,182 Cross currency swaps (3) $ — $ 2,797 $ — $ 2,797 Foreign currency exchange contracts (3) $ — $ 609 $ — $ 609 Liabilities Foreign currency exchange contracts (3) $ — $ 4,821 $ — $ 4,821 Deferred compensation (4) $ 1,182 $ — $ — $ 1,182 (in thousands) As of December 31, 2019 Quoted Prices Significant Significant Balance at December 31, 2019  Assets Money market funds (1) $ 71 $ — $ — $ 71 Equity mutual funds (2) $ 1,676 $ — $ — $ 1,676 Cross currency swaps (3) $ — $ 4,559 $ — $ 4,559 Foreign currency exchange contracts (3) $ — $ 1,791 $ — $ 1,791 Liabilities Foreign currency exchange contracts (3) $ — $ 2,886 $ — $ 2,886 Deferred compensation (4) $ 1,676 $ — $ — $ 1,676 (1) Money market funds with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of September 30, 2020 and December 31, 2019, consisted of demand deposits. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets. See footnote (4) below for a discussion of the related deferred compensation liability. (3) Cross currency swaps and foreign currency exchange contracts are included within other current assets, other long-term assets, accrued liabilities, or other long-term liabilities depending on the gain (loss) position and anticipated settlement date.

Hedging Instruments (Tables)

Hedging Instruments (Tables)	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Details of net investment hedges and Income Statement impact of hedging instruments	The following tables present the effect of cash flow hedge accounting on our unaudited condensed consolidated statements of income and comprehensive income, and provide information regarding the location and amounts of pretax gains or losses of derivatives: (in thousands) Three Months Ended September 30,  2020 2019 Financial statement line items in which effects of cash flow hedges are recorded Cost of revenue $ 299,183 $ 260,353 Foreign exchange contracts Amount of gain (loss) reclassified from accumulated other comprehensive income into income $ (591) $ 3,171 (in thousands) Nine Months Ended September 30,  2020 2019 Financial statement line items in which effects of cash flow hedges are recorded Cost of revenue $ 824,179 $ 767,062 Foreign exchange contracts Amount of gain reclassified from accumulated other comprehensive income into income $ 2,562 $ 7,091
Schedule of hedging instruments	The fair values of hedging instruments and their respective classification on our unaudited condensed consolidated balance sheets and amounts subject to offset under master netting arrangements consisted of the following derivative instruments, unless otherwise noted: (in thousands) Hedging Assets  September 30, 2020 December 31, 2019  Derivatives and non-derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Other current assets $ 519 $ 1,791 Cross currency swaps Other long-term assets 2,797 4,559 Foreign currency exchange contracts Other long-term assets 90 — Total derivative instruments presented as hedge instruments on the balance sheet 3,406 6,350 Gross amounts subject to master netting arrangements not offset on the balance sheet (609) (1,354) Net amount $ 2,797 $ 4,996 ໿ (in thousands) Hedging Liabilities  September 30, 2020 December 31, 2019  Derivatives and non-derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Accrued liabilities $ 3,631 $ 2,886 Foreign currency exchange contracts Other long-term liabilities 1,190 — Total derivative instruments presented as cash flow hedges on the balance sheet 4,821 2,886 Non-derivative foreign currency denominated debt designated as net investment hedge on the balance sheet (1) Long-term debt 103,980 99,422 Total hedging instruments presented on the balance sheet 108,801 102,308 Gross amounts subject to master netting arrangements not offset on the balance sheet (609) (1,354) Net amount $ 108,192 $ 100,954 (1) Amounts represent reported carrying amounts of our foreign currency denominated debt. See “Note 18. Fair Value Measurements” for information regarding the fair value of our long-term debt.

Accounting Policies (Details)

Accounting Policies (Details) - USD ($) $ in Thousands	Jan. 01, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounting Standards Update [Extensible List]		us-gaap:AccountingStandardsUpdate201613Member
Non-cash cumulative effect adjustment to retained earnings, net of tax		$ 441,115	$ 273,400	$ 108,055	$ 177,825	$ 202,722	$ 171,549	$ 51,870	$ (9,233)
Reserve for contract assets and sales-type leases		3,300
Accounts receivable allowance for credit losses		6,600			3,600
Cumulative effect of accounting changes (Note 2)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Non-cash cumulative effect adjustment to retained earnings, net of tax					(1,829)
Accounting Standards Update 2016-13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reserve for contract assets and sales-type leases	$ 2,300
Accounts receivable allowance for credit losses	200
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Non-cash cumulative effect adjustment to retained earnings, net of tax		$ 2,000,805	$ 1,854,586	$ 1,705,646	1,595,648	$ 1,505,152	$ 1,396,315	$ 1,270,609	$ 1,167,928
Retained Earnings | Cumulative effect of accounting changes (Note 2)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Non-cash cumulative effect adjustment to retained earnings, net of tax					(1,829)
Retained Earnings | Accounting Standards Update 2016-13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Non-cash cumulative effect adjustment to retained earnings, tax	$ 600
Retained Earnings | Accounting Standards Update 2016-13 | Cumulative effect of accounting changes (Note 2)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Non-cash cumulative effect adjustment to retained earnings, net of tax					$ 1,800

Revenue Recognition (General Na

Revenue Recognition (General Narrative) (Details)	9 Months Ended
	Sep. 30, 2020
Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Payment term	30 days
Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Payment term	60 days

Revenue Recognition (Lease Reve

Revenue Recognition (Lease Revenue) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
Lease revenue	$ 4.5	$ 5.3	$ 12.2	$ 14.5

Revenue Recognition (Extended W

Revenue Recognition (Extended Warranties and Post-Contract Support) (Details) - Extended warranties and post contract support - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Post-contract support contract, term		12 months
Deferred revenue	$ 35.2	$ 35.2	$ 38
Deferred revenue recognized	2.8	19.5
Estimation of future revenues	$ 21.2	$ 21.2
Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Extended product warranty, term		1 year
Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Extended product warranty, term		5 years

Revenue Recognition (Remaining

Revenue Recognition (Remaining Performance Obligation) (Details)	Sep. 30, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01 | Extended warranties and post contract support
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	11.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01 | Up front customer loyalty programs and volume commitment programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	7.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01 | Instrument rebate programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	10.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01 | Reagent rental programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	11.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Extended warranties and post contract support
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	40.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Up front customer loyalty programs and volume commitment programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	25.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Instrument rebate programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	34.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Reagent rental programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	37.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Extended warranties and post contract support
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	28.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Up front customer loyalty programs and volume commitment programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	23.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Instrument rebate programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	25.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Reagent rental programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	24.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Extended warranties and post contract support
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	14.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Up front customer loyalty programs and volume commitment programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	20.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Instrument rebate programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	16.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Reagent rental programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	13.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Extended warranties and post contract support
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	7.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Up front customer loyalty programs and volume commitment programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	25.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Instrument rebate programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	15.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Reagent rental programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percentage	15.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period

Revenue Recognition (SaaS Subsc

Revenue Recognition (SaaS Subscriptions) (Details)	9 Months Ended
	Sep. 30, 2020
Maximum
Disaggregation of Revenue [Line Items]
SaaS Subscription, term of contract	2 years

Revenue Recognition (Up-Front C

Revenue Recognition (Up-Front Customer Loyalty Programs) (Details) - Up front customer loyalty programs - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Capitalized customer acquisition costs	$ 146	$ 146	$ 137.4
Recognized as a reduction of revenue	$ 9.7	$ 29.9

Revenue Recognition (Volume Com

Revenue Recognition (Volume Commitment Programs) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Volume commitment programs
Disaggregation of Revenue [Line Items]
Commitment contract assets	$ 101.3	$ 101.3	$ 83.9
Commitment contract assets reclassified to accounts receivable	4.5	14
Up front customer loyalty programs and volume commitment programs
Disaggregation of Revenue [Line Items]
Estimation of future revenues	$ 2,000	$ 2,000

Revenue Recognition (Instrument

Revenue Recognition (Instrument Rebate Programs) (Details) - Instrument rebate programs - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	$ 41	$ 41	$ 49.1
Deferred revenue recognized	$ 4	$ 12.5

Revenue Recognition (Reagent Re

Revenue Recognition (Reagent Rental Programs) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Lease receivable asset	$ 9.2		$ 9.2		$ 7.2
Lease receivable asset reclassified to accounts receivable	0.3		1
Operating-type reagent rental programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Instruments transferred to property and equipment	2.6	$ 5.5	6.6	$ 10.5
Reagent rental programs
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Estimation of future revenues	$ 25.9		$ 25.9

Revenue Recognition (Disaggrega

Revenue Recognition (Disaggregation of Revenue by Major Product and Service Categories) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenue	$ 721,789	$ 605,303	$ 1,985,717	$ 1,801,462
CAG segment revenue
Disaggregation of Revenue [Line Items]
Total revenue	638,017	533,130	1,756,113	1,589,397
Water segment revenue
Disaggregation of Revenue [Line Items]
Total revenue	33,272	34,906	95,537	99,980
LPD segment revenue
Disaggregation of Revenue [Line Items]
Total revenue	36,971	31,370	103,369	95,980
Other segment revenue
Disaggregation of Revenue [Line Items]
Total revenue	13,529	5,897	30,698	16,105
Cag Diagnostics recurring revenue | CAG segment revenue
Disaggregation of Revenue [Line Items]
Total revenue	567,416	460,974	1,565,595	1,382,196
IDEXX VetLab consumables | CAG segment revenue
Disaggregation of Revenue [Line Items]
Total revenue	218,605	177,276	603,379	519,646
Rapid assay products | CAG segment revenue
Disaggregation of Revenue [Line Items]
Total revenue	70,593	58,930	192,681	181,966
Reference laboratory diagnostic and consulting services | CAG segment revenue
Disaggregation of Revenue [Line Items]
Total revenue	254,223	204,919	703,300	621,469
CAG Diagnostics services and accessories | CAG segment revenue
Disaggregation of Revenue [Line Items]
Total revenue	23,995	19,849	66,235	59,115
CAG Diagnostics capital - instruments | CAG segment revenue
Disaggregation of Revenue [Line Items]
Total revenue	29,336	32,608	72,040	92,883
Veterinary software, services and diagnostic imaging systems | CAG segment revenue
Disaggregation of Revenue [Line Items]
Total revenue	$ 41,265	$ 39,548	$ 118,478	$ 114,318

Revenue Recognition (Disaggre_2

Revenue Recognition (Disaggregation of Revenue by Principal Geographic Area, Based on Customers' Domiciles) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenue	$ 721,789	$ 605,303	$ 1,985,717	$ 1,801,462
United States
Disaggregation of Revenue [Line Items]
Total revenue	454,836	380,184	1,257,617	1,127,347
Europe, the Middle East and Africa
Disaggregation of Revenue [Line Items]
Total revenue	147,193	122,050	400,928	368,636
Asia Pacific Region
Disaggregation of Revenue [Line Items]
Total revenue	77,401	64,648	212,663	188,756
Canada
Disaggregation of Revenue [Line Items]
Total revenue	28,710	24,334	78,314	75,212
Latin America
Disaggregation of Revenue [Line Items]
Total revenue	$ 13,649	$ 14,087	$ 36,195	$ 41,511

Revenue Recognition (Costs to O

Revenue Recognition (Costs to Obtain a Contract) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Deferred commission costs	$ 16.5	$ 16.5	$ 15.6
Commissions expense recognized	$ 1.3	$ 4
Minimum
Disaggregation of Revenue [Line Items]
Amortization period	3 years	3 years
Maximum
Disaggregation of Revenue [Line Items]
Amortization period	7 years	7 years

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2020
Business Acquisition [Line Items]
Goodwill		$ 239,724	$ 238,100
Midwest U.S.-based multi-site reference laboratory
Business Acquisition [Line Items]
Consideration transferred		$ 50,000
Intangible assets acquired	$ 26,900
Tangible assets acquired	200
Goodwill	$ 22,900
Customer Relationships | Midwest U.S.-based multi-site reference laboratory
Business Acquisition [Line Items]
Weighted average useful life of finite-lived intangible assets (in years)	13 years 9 months 18 days

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Fair value of share-based compensation awards, granted	$ 1.3	$ 3.8	$ 39.9	$ 40.1
Unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding	64		$ 64
Weighted average recognition period for unrecognized compensation expense, in years			1 year 8 months 12 days
Share-based compensation expense	$ 7.9	$ 9.4	$ 23	$ 22.6

Share-Based Compensation (Assum

Share-Based Compensation (Assumptions Used) (Details) - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Share price at grant (in dollars per share)	$ 290.15	$ 213.35
Expected stock price volatility	27.00%	26.00%
Expected term, in years	6 years	6 years
Risk-free interest rate	1.40%	2.40%
Weighted average fair value of options granted (in dollars per share)	$ 84.60	$ 64.99

Credit Losses (Details)

Credit Losses (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable allowance for credit losses	$ 6.6	$ 3.6
Percent of accounts receivable not past due	88.00%	84.00%
Percent of accounts receivable past due	12.00%	16.00%
Accounts receivable, noncurrent, threshold period past due	60 days	60 days
Reserve for contract assets and sales-type leases	$ 3.3
Greater than 60 Days Past Due
Financing Receivable, Allowance for Credit Loss [Line Items]
Percent of accounts receivable past due	1.70%	1.50%

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory, Net [Abstract]
Raw materials	$ 46,791	$ 41,202
Work-in-process	19,582	20,077
Finished goods	151,224	133,740
Inventories	$ 217,597	$ 195,019

Leases (Maturities of Operating

Leases (Maturities of Operating Lease Liabilities) (Details) $ in Thousands	Sep. 30, 2020USD ($)
Leases [Abstract]
2020 (remainder of year)	$ 3,824
2021	20,660
2022	17,572
2023	12,453
2024	8,280
Thereafter	39,188
Total lease payments	101,977
Less imputed interest	(14,724)
Total	$ 87,253

Leases (Supplemental Cash Flow

Leases (Supplemental Cash Flow Information) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of operating leases liabilities	$ 14,619	$ 14,878
Right-of-use assets obtained in exchange for operating lease obligations, net of early lease terminations	$ 17,064	$ 7,870

Other Current and Long-Term A_3

Other Current and Long-Term Assets (Schedule Of Other Current Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Other Assets, Noncurrent [Abstract]
Customer acquisition costs	$ 42,906	$ 39,329
Prepaid expenses	35,966	31,992
Taxes receivable	24,051	20,516
Contract assets, net	20,361	17,659
Deferred sales commissions	5,510	5,202
Other assets	9,108	10,284
Other current assets	$ 137,902	$ 124,982

Other Current and Long-Term A_4

Other Current and Long-Term Assets (Schedule Of Other Long-term Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Other Assets, Noncurrent [Abstract]
Customer acquisition costs	$ 103,075	$ 98,117
Contract assets, net	80,936	66,226
Investment in long-term product supply arrangements	12,599	13,657
Deferred sales commissions	10,993	10,442
Deferred income taxes	8,198	8,100
Taxes receivable	6,329	14,960
Other assets	32,672	28,690
Other long-term assets	$ 254,802	$ 240,192

Accrued Liabilities (Schedule O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accrued Liabilities, Current [Abstract]
Accrued employee compensation and related expenses	$ 133,032	$ 127,174
Accrued expenses	100,798	86,296
Accrued customer incentives and refund obligations	71,885	63,079
Accrued taxes	40,013	31,108
Current lease liabilities	16,598	15,281
Accrued liabilities	$ 362,326	$ 322,938

Accrued Liabilities (Schedule_2

Accrued Liabilities (Schedule Of Other Long-term Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accrued Liabilities, Current [Abstract]
Accrued taxes	$ 59,663	$ 67,463
Other accrued long-term expenses	20,001	13,701
Other long-term liabilities	$ 79,664	$ 81,164

Debt (Schedule of Current Senio

Debt (Schedule of Current Senior Notes Outstanding) (Details) - Senior Notes	Sep. 30, 2020USD ($)	Sep. 30, 2020EUR (€)	Apr. 14, 2020USD ($)	Apr. 10, 2020	Apr. 02, 2020USD ($)
2023 Series A Notes
Line of Credit Facility [Line Items]
Principal Amount	$ 75,000,000
Coupon Rate	3.94%	3.94%
2025 Series B Notes
Line of Credit Facility [Line Items]
Principal Amount	$ 75,000,000
Coupon Rate	4.04%	4.04%
2026 Senior Notes
Line of Credit Facility [Line Items]
Principal Amount	$ 75,000,000
Coupon Rate	3.72%	3.72%
2021 Series A Notes
Line of Credit Facility [Line Items]
Principal Amount	$ 50,000,000
Coupon Rate	3.32%	3.32%
2024 Series B Notes
Line of Credit Facility [Line Items]
Principal Amount	$ 75,000,000
Coupon Rate	3.76%	3.76%
2025 Series C Notes
Line of Credit Facility [Line Items]
Principal Amount | €		€ 88,857,000
Coupon Rate	1.785%	1.785%
2022 Series A Notes
Line of Credit Facility [Line Items]
Principal Amount	$ 75,000,000
Coupon Rate	3.25%	3.25%
2027 Series B Notes
Line of Credit Facility [Line Items]
Principal Amount	$ 75,000,000
Coupon Rate	3.72%	3.72%
2029 Series C Notes
Line of Credit Facility [Line Items]
Principal Amount	$ 100,000,000
Coupon Rate	4.19%	4.19%
MetLife 2030 Series D Notes
Line of Credit Facility [Line Items]
Principal Amount	$ 125,000,000				$ 125,000,000
Coupon Rate	2.50%	2.50%			2.50%
Prudential 2030 Series D Notes
Line of Credit Facility [Line Items]
Principal Amount	$ 75,000,000		$ 75,000,000
Coupon Rate	2.50%	2.50%		2.50%

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($)	Apr. 14, 2020	Dec. 04, 2015	Sep. 30, 2020	Apr. 10, 2020	Apr. 02, 2020	Mar. 23, 2020	Mar. 22, 2020
MetLife
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity						$ 300,000,000	$ 150,000,000
Prudential
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity				$ 425,000,000
Revolving Credit Facility
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 1,000,000,000	$ 850,000,000
Debt instrument term	3 years	5 years
Line of credit facility, increase limit	$ 250,000,000
Line of credit facility, higher borrowing capacity option	1,250,000,000
Revolving Credit Facility, Individual Borrowings | Minimum
Line of Credit Facility [Line Items]
Debt instrument term			30 days
Revolving Credit Facility, Individual Borrowings | Maximum
Line of Credit Facility [Line Items]
Debt instrument term			180 days
Senior Notes
Line of Credit Facility [Line Items]
Debt covenant, maximum consolidated leverage ratio			3.5
MetLife 2030 Series D Notes | Senior Notes
Line of Credit Facility [Line Items]
Debt instrument, face amount			$ 125,000,000		$ 125,000,000
Stated interest rate			2.50%		2.50%
Prudential 2030 Series D Notes | Senior Notes
Line of Credit Facility [Line Items]
Debt instrument, face amount	$ 75,000,000		$ 75,000,000
Stated interest rate			2.50%	2.50%

Repurchases of Common Stock (De

Repurchases of Common Stock (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Equity [Abstract]
Shares repurchased in the open market (in shares)	0	330	721	683
Shares acquired through employee surrender for statutory tax withholding (in shares)	1	1	31	38
Total shares repurchased (in shares)	1	331	752	721
Cost of shares repurchased in the open market	$ 0	$ 91,051	$ 179,623	$ 165,198
Cost of shares for employee surrenders	360	277	9,029	7,849
Total cost of shares	$ 360	$ 91,328	$ 188,652	$ 173,047
Average cost per share - open market repurchases (in dollars per share)	$ 0	$ 275.50	$ 249.20	$ 241.56
Average cost per share - employee surrenders (in dollars per share)	393.12	286.65	292.03	209.20
Average cost per share - total (in dollars per share)	$ 393.12	$ 275.53	$ 250.96	$ 239.87

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Effective income tax rate	10.80%	18.00%	16.00%	18.50%

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Schedule Of AOCI) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance beginning of period	$ 177,825	$ (9,233)
Other comprehensive (loss) income before reclassifications	(13,707)	2,022
Gains (losses) reclassified from accumulated other comprehensive income	(2,036)	(5,796)
Balance end of period	441,115	202,722
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance beginning of period	(46,182)	(41,791)
Balance end of period	(61,925)	(45,565)
Unrealized Gain (Loss) on Investments, Net of Tax
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance beginning of period	110	(157)
Other comprehensive (loss) income before reclassifications	(408)	295
Gains (losses) reclassified from accumulated other comprehensive income	0	0
Balance end of period	(298)	138
Foreign Currency Exchange Contracts
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance beginning of period	(736)	6,229
Other comprehensive (loss) income before reclassifications	(623)	6,458
Gains (losses) reclassified from accumulated other comprehensive income	(2,036)	(5,796)
Balance end of period	(3,395)	6,891
Euro-Denominated Notes
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance beginning of period	1,396	(394)
Other comprehensive (loss) income before reclassifications	(3,466)	3,507
Gains (losses) reclassified from accumulated other comprehensive income	0	0
Balance end of period	(2,070)	3,113
Cross Currency Swaps
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance beginning of period	3,467	1,360
Other comprehensive (loss) income before reclassifications	(1,339)	3,993
Gains (losses) reclassified from accumulated other comprehensive income	0	0
Balance end of period	2,128	5,353
Cumulative Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance beginning of period	(50,419)	(48,829)
Other comprehensive (loss) income before reclassifications	(7,871)	(12,231)
Gains (losses) reclassified from accumulated other comprehensive income	0	0
Balance end of period	$ (58,290)	$ (61,060)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Income (Schedule of Reclassifications out of AOCI) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Cost of revenue	$ 299,183			$ 260,353			$ 824,179	$ 767,062
Tax expense	17,633			23,960			77,376	76,464
Gain (loss), net of tax	146,321	$ 148,996	$ 111,856	108,838	$ 125,701	$ 102,709	407,173	337,248
Accumulated Net Gain (Loss) from Cash Flow Hedges | Amount of (Loss) Gain Reclassified from Accumulated Other Comprehensive Income into Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Cost of revenue	(591)			3,171			2,562	7,091
Tax expense	(53)			688			526	1,295
Gain (loss), net of tax	$ (538)			$ 2,483			$ 2,036	$ 5,796

Earnings Per Share (Schedule Of

Earnings Per Share (Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share) (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Shares outstanding for basic earnings per share:
Shares outstanding for basic earnings per share (in shares)	85,314	86,198	85,293	86,206
Shares outstanding for diluted earnings per share:
Shares outstanding for basic earnings per share (in shares)	85,314	86,198	85,293	86,206
Dilutive effect of share-based payment awards (in shares)	1,376	1,469	1,342	1,427
Shares outstanding for diluted earnings per share (in shares)	86,690	87,667	86,635	87,633

Earnings Per Share (Schedule _2

Earnings Per Share (Schedule Of Number Of Anti-Dilutive Stock Options) (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of shares underlying anti-dilutive shares (in shares)	1	0	0	0
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of shares underlying anti-dilutive shares (in shares)	10	29	236	247

Commitments, Contingencies an_2

Commitments, Contingencies and Guarantees (Details) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
Damages sought	$ 50
Loss contingency accrual	$ 27.5

Segment Reporting (Allocated Co

Segment Reporting (Allocated Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Cost of sales	$ 299,183	$ 260,353	$ 824,179	$ 767,062
Gross profit	422,606	344,950	1,161,538	1,034,400
Operating Expenses:
Sales and marketing	108,202	104,551	318,526	312,499
General and administrative	105,031	66,337	231,111	186,653
Research and development	37,517	34,260	102,472	98,033
Income from operations	171,856	139,802	509,429	437,215
Operating Segments | CAG
Operating Expenses:
Income from operations	139,434	117,691	426,062	370,600
Operating Segments | Water
Operating Expenses:
Income from operations	15,243	16,930	43,383	47,467
Operating Segments | LPD
Operating Expenses:
Income from operations	10,505	4,850	28,417	17,707
Operating Segments | Other
Operating Expenses:
Income from operations	$ 6,674	331	$ 11,567	1,441
Restatement Adjustment | Operating Segments | CAG
Segment Reporting Information [Line Items]
Cost of sales		(428)		(266)
Gross profit		428		266
Operating Expenses:
Sales and marketing		211		322
General and administrative		2,472		1,377
Research and development		4,544		12,062
Total operating expenses		7,227		13,761
Income from operations		(6,799)		(13,495)
Restatement Adjustment | Operating Segments | Water
Segment Reporting Information [Line Items]
Cost of sales		(19)		(12)
Gross profit		19		12
Operating Expenses:
Sales and marketing		9		14
General and administrative		105		(114)
Research and development		20		39
Total operating expenses		134		(61)
Income from operations		(115)		73
Restatement Adjustment | Operating Segments | LPD
Segment Reporting Information [Line Items]
Cost of sales		(24)		(15)
Gross profit		24		15
Operating Expenses:
Sales and marketing		12		18
General and administrative		131		(122)
Research and development		25		49
Total operating expenses		168		(55)
Income from operations		(144)		70
Restatement Adjustment | Operating Segments | Other
Segment Reporting Information [Line Items]
Cost of sales		(10)		(6)
Gross profit		10		6
Operating Expenses:
Sales and marketing		0		0
General and administrative		1,058		2,222
Research and development		0		0
Total operating expenses		1,058		2,222
Income from operations		(1,048)		(2,216)
Previously Reported | Unallocated
Segment Reporting Information [Line Items]
Cost of sales		481		299
Gross profit		(481)		(299)
Operating Expenses:
Sales and marketing		(232)		(354)
General and administrative		(3,766)		(3,363)
Research and development		(4,589)		(12,150)
Total operating expenses		(8,587)		(15,867)
Income from operations		$ 8,106		$ 15,568

Segment Reporting (Summary of S

Segment Reporting (Summary of Segment Performance) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Revenue	$ 721,789			$ 605,303			$ 1,985,717	$ 1,801,462
Income from operations	171,856			139,802			509,429	437,215
Interest expense, net	(7,902)			(7,004)			(24,880)	(23,503)
Income before provision for income taxes	163,954			132,798			484,549	413,712
Provision for income taxes	17,633			23,960			77,376	76,464
Net income	146,321	$ 148,996	$ 111,856	108,838	$ 125,701	$ 102,709	407,173	337,248
Less: Net income attributable to noncontrolling interest	102			1			187	24
Net income attributable to IDEXX Laboratories, Inc. stockholders	146,219			108,837			406,986	337,224
CAG
Segment Reporting Information [Line Items]
Revenue	638,017			533,130			1,756,113	1,589,397
Water
Segment Reporting Information [Line Items]
Revenue	33,272			34,906			95,537	99,980
LPD
Segment Reporting Information [Line Items]
Revenue	36,971			31,370			103,369	95,980
Other
Segment Reporting Information [Line Items]
Revenue	13,529			5,897			30,698	16,105
Operating Segments | CAG
Segment Reporting Information [Line Items]
Revenue	638,017			533,130			1,756,113	1,589,397
Income from operations	139,434			117,691			426,062	370,600
Operating Segments | Water
Segment Reporting Information [Line Items]
Revenue	33,272			34,906			95,537	99,980
Income from operations	15,243			16,930			43,383	47,467
Operating Segments | LPD
Segment Reporting Information [Line Items]
Revenue	36,971			31,370			103,369	95,980
Income from operations	10,505			4,850			28,417	17,707
Operating Segments | Other
Segment Reporting Information [Line Items]
Revenue	13,529			5,897			30,698	16,105
Income from operations	$ 6,674			$ 331			$ 11,567	$ 1,441

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Estimated fair value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value disclosure	$ 998.5	$ 753.6
Carrying value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value disclosure	$ 904	$ 699.4

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule of Assets and Liabilities) (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	$ 76	$ 71
Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	76	71
Money market funds | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	0	0
Money market funds | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	0	0
Equity mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity mutual fund	1,182	1,676
Equity mutual funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity mutual fund	1,182	1,676
Equity mutual funds | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity mutual fund	0	0
Equity mutual funds | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity mutual fund	0	0
Cross Currency Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	2,797	4,559
Cross Currency Swaps | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	0	0
Cross Currency Swaps | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	2,797	4,559
Cross Currency Swaps | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	0	0
Foreign currency exchange contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	609	1,791
Derivative liability	4,821	2,886
Foreign currency exchange contracts | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	0	0
Derivative liability	0	0
Foreign currency exchange contracts | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	609	1,791
Derivative liability	4,821	2,886
Foreign currency exchange contracts | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	0	0
Derivative liability	0	0
Deferred compensation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation	1,182	1,676
Deferred compensation | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation	1,182	1,676
Deferred compensation | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation	0	0
Deferred compensation | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation	$ 0	$ 0

Hedging Instruments (Narrative)

Hedging Instruments (Narrative) (Details) $ in Thousands	Jun. 18, 2025USD ($)	Jun. 30, 2023USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020EUR (€)	Dec. 31, 2019USD ($)	Jun. 30, 2015EUR (€)
Derivative [Line Items]
Estimated net amount of losses expected to be reclassified out of accumulated other comprehensive income and into earnings within next 12 months					$ 2,500
Cash flow hedge, hedge percentage of estimated exposure from intercompany products purchases and sales					85.00%
General duration of foreign currency exchange contracts					24 months
Derivative, notional amount			$ 208,600		$ 208,600			$ 210,900
Unrealized gain (loss) on Euro-denominated notes, net of tax			(2,824)	$ 3,007	(3,466)	$ 3,507
Unrealized gain (loss) on cross currency swaps, net of tax			(3,941)	3,125	(1,339)	3,993
Excluded component recognized as reduction of interest			$ 700	$ 600	$ 2,000	$ 1,700
Series C Senior Note
Derivative [Line Items]
Debt instrument, face amount | €									€ 88,900,000
Stated interest rate									1.785%
Derivatives and non-derivatives designated as hedging instruments | Cross Currency Swaps
Derivative [Line Items]
Derivative, notional amount | €							€ 90,000,000
Derivatives and non-derivatives designated as hedging instruments | Cross Currency Swaps
Derivative [Line Items]
Derivative, notional amount | €							€ 10,000,000
Scenario, Forecast | Derivatives and non-derivatives designated as hedging instruments | Cross Currency Swaps
Derivative [Line Items]
Proceeds from hedge		$ 104,500
Scenario, Forecast | Derivatives and non-derivatives designated as hedging instruments | Cross Currency Swaps
Derivative [Line Items]
Proceeds from hedge	$ 11,400

Hedging Instruments (Derivative

Hedging Instruments (Derivatives Designated In Cash Flow Hedging Relationships) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Foreign Currency Fair Value Hedge Derivative [Line Items]
Cost of revenue	$ 299,183	$ 260,353	$ 824,179	$ 767,062
Foreign currency exchange contracts | Costs of revenue
Foreign Currency Fair Value Hedge Derivative [Line Items]
Amount of gain (loss) reclassified from accumulated other comprehensive income into income	$ (591)	$ 3,171	$ 2,562	$ 7,091

Hedging Instruments (Schedule O

Hedging Instruments (Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments) (Details) - Derivatives and non-derivatives designated as hedging instruments - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Total derivative instruments presented as hedge instruments on the balance sheet	$ 3,406	$ 6,350
Gross amounts subject to master netting arrangements not offset on the balance sheet	(609)	(1,354)
Net amount	2,797	4,996
Total hedging instruments presented on the balance sheet	108,801	102,308
Gross amounts subject to master netting arrangements not offset on the balance sheet	(609)	(1,354)
Net amount	108,192	100,954
Cross currency swaps | Other long-term assets
Derivatives, Fair Value [Line Items]
Total derivative instruments presented as hedge instruments on the balance sheet	2,797	4,559
Foreign currency borrowings designated as net investment hedge on the balance sheet | Long-term debt
Derivatives, Fair Value [Line Items]
Total hedging instruments presented on the balance sheet	103,980	99,422
Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Total hedging instruments presented on the balance sheet	4,821	2,886
Cash Flow Hedging | Foreign currency exchange contracts | Other current assets
Derivatives, Fair Value [Line Items]
Total derivative instruments presented as hedge instruments on the balance sheet	519	1,791
Cash Flow Hedging | Foreign currency exchange contracts | Other long-term assets
Derivatives, Fair Value [Line Items]
Total derivative instruments presented as hedge instruments on the balance sheet	90	0
Cash Flow Hedging | Foreign currency exchange contracts | Accrued liabilities
Derivatives, Fair Value [Line Items]
Total hedging instruments presented on the balance sheet	3,631	2,886
Cash Flow Hedging | Foreign currency exchange contracts | Other long-term liabilities
Derivatives, Fair Value [Line Items]
Total hedging instruments presented on the balance sheet	$ 1,190	$ 0